{"metadata":{"kernelspec":{"language":"python","display_name":"Python 3","name":"python3"},"language_info":{"name":"python","version":"3.11.13","mimetype":"text/x-python","codemirror_mode":{"name":"ipython","version":3},"pygments_lexer":"ipython3","nbconvert_exporter":"python","file_extension":".py"},"kaggle":{"accelerator":"gpu","dataSources":[{"sourceId":4582225,"sourceType":"datasetVersion","datasetId":2672707},{"sourceId":12899586,"sourceType":"datasetVersion","datasetId":8161862}],"dockerImageVersionId":31192,"isInternetEnabled":true,"language":"python","sourceType":"notebook","isGpuEnabled":true}},"nbformat_minor":4,"nbformat":4,"cells":[{"cell_type":"markdown","source":"# Introduction\n\nThe aim of this project is to create a model to classify clinical trial records (protocol text, inclusion/exclusion) to predict whether trial was completed, terminated, or withdrawn.\n\n[This paper]() states that there are four main factors that determine whether a trial is successful:\n- quality of clinical trials\n- speed of clinical trials - \"the shorter the clinical trial period, the lower the clinical trial cost, thereby reducing the financial burden on the company.\"\n- relationship type - \"diversity of collaboration\" with many partners (especially hugh-quality partners with proven track records) are a good indicator of success\n- communication - having an infrastructure for exchanging information between collaborators\n\nThe paper goes on to state that: \"the most important features for predicting success of drug approval ... are trial outcomes, trial status, trial accrual rates, duration, prior approval for another indication, and the sponsor’s track record.\"\n\n# Getting and Cleaning the Data\n\nThe main data source for detailed info about clinical trials is [ClinicalTrials.gov]()'s API. [Info about the contents of that is found here](https://clinicaltrials.gov/data-api/about-api/study-data-structure).\n\n However, for initial investigation, it will be sufficient to use data from Kaggle datasets:\n - [Clinical Trials, the Devastator](https://www.kaggle.com/datasets/thedevastator/a-quick-overview-of-clinical-trials) - contains many potentially informative features for each trial including (crucially) titles and text summaries, enrollment numbers, start/end dates etc. However, the only target variable is `status`, the values of which are Completed, Terminated, Active, Recruiting, etc. which we will use as a proxy for the success of the trial.","metadata":{}},{"cell_type":"code","source":"# Clear CUDA cache between runs to avoid OutOfMemory errors\nimport torch, gc\ngc.collect()\ntorch.cuda.empty_cache()","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:11:42.857980Z","iopub.execute_input":"2025-11-13T14:11:42.858180Z","iopub.status.idle":"2025-11-13T14:11:44.568340Z","shell.execute_reply.started":"2025-11-13T14:11:42.858163Z","shell.execute_reply":"2025-11-13T14:11:44.567645Z"}},"outputs":[],"execution_count":1},{"cell_type":"code","source":"import numpy as np\nimport pandas as pd\nimport os\nfrom pathlib import Path\n\n# ! pip install -q datasets","metadata":{"_uuid":"8f2839f25d086af736a60e9eeb907d3b93b6e0e5","_cell_guid":"b1076dfc-b9ad-4769-8c92-a6c4dae69d19","trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:11:44.569157Z","iopub.execute_input":"2025-11-13T14:11:44.569495Z","iopub.status.idle":"2025-11-13T14:11:44.845214Z","shell.execute_reply.started":"2025-11-13T14:11:44.569476Z","shell.execute_reply":"2025-11-13T14:11:44.844506Z"}},"outputs":[],"execution_count":2},{"cell_type":"markdown","source":"## Getting the Data","metadata":{}},{"cell_type":"code","source":"trial_info = pd.read_csv(\"../input/a-quick-overview-of-clinical-trials/AERO-BirdsEye-Data.csv\")","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:11:44.847307Z","iopub.execute_input":"2025-11-13T14:11:44.847662Z","iopub.status.idle":"2025-11-13T14:11:45.003226Z","shell.execute_reply.started":"2025-11-13T14:11:44.847643Z","shell.execute_reply":"2025-11-13T14:11:45.002590Z"}},"outputs":[],"execution_count":3},{"cell_type":"markdown","source":"## Exploring the Data","metadata":{}},{"cell_type":"code","source":"trial_info","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:11:45.004007Z","iopub.execute_input":"2025-11-13T14:11:45.004280Z","iopub.status.idle":"2025-11-13T14:11:45.019816Z","shell.execute_reply.started":"2025-11-13T14:11:45.004260Z","shell.execute_reply":"2025-11-13T14:11:45.018987Z"}},"outputs":[{"execution_count":4,"output_type":"execute_result","data":{"text/plain":"       index          NCT Sponsor  \\\n0          0  NCT00003305  Sanofi   \n1          1  NCT00003821  Sanofi   \n2          2  NCT00004025  Sanofi   \n3          3  NCT00005645  Sanofi   \n4          4  NCT00008281  Sanofi   \n...      ...          ...     ...   \n13743  13743  NCT03726879   Roche   \n13744  13744  NCT03735121   Roche   \n13745  13745  NCT03761849   Roche   \n13746  13746  NCT03762681   Roche   \n13747  13747  NCT03779334   Roche   \n\n                                                   Title  \\\n0      A Phase II Trial of Aminopterin in Adults and ...   \n1      Phase II Trial of Aminopterin in Patients With...   \n2      Phase I/II Trial of the Safety, Immunogenicity...   \n3      Phase II Trial of ILX295501 Administered Orall...   \n4      A Multicenter, Open-Label, Randomized, Three-A...   \n...                                                  ...   \n13743  A Phase III, Randomized, Double-Blind, Placebo...   \n13744  A Two-Part Phase Ib/II Study to Investigate th...   \n13745  A Randomized, Multicenter, Double-Blind, Place...   \n13746  A Randomized, Placebo-controlled,Observer-blin...   \n13747  An Open-Label Study of Risdiplam in Infants Wi...   \n\n                                                 Summary  Start_Year  \\\n0      RATIONALE: Drugs used in chemotherapy use diff...        1997   \n1      RATIONALE: Drugs used in chemotherapy use diff...        1998   \n2      RATIONALE: Vaccines made from a person's white...        1999   \n3      RATIONALE: Drugs used in chemotherapy use diff...        1999   \n4      RATIONALE: Drugs used in chemotherapy use diff...        2000   \n...                                                  ...         ...   \n13743  This study (also known as IMpassion050) will e...        2018   \n13744  This study will evaluate the pharmacokinetics,...        2018   \n13745  This study will evaluate the efficacy, safety,...        2018   \n13746  This study is designed to assess the safety, t...        2018   \n13747  A global study of oral risdiplam in pre-sympto...        2019   \n\n       Start_Month            Phase  Enrollment              Status  \\\n0                7          Phase 2          75           Completed   \n1                1          Phase 2           0           Withdrawn   \n2                3  Phase 1/Phase 2          36      Unknown status   \n3                5          Phase 2           0           Withdrawn   \n4               10          Phase 3           0      Unknown status   \n...            ...              ...         ...                 ...   \n13743           12          Phase 3         224          Recruiting   \n13744           12          Phase 1         245          Recruiting   \n13745           12          Phase 3         660  Not yet recruiting   \n13746           12          Phase 1          75  Not yet recruiting   \n13747            2          Phase 2          25  Not yet recruiting   \n\n                      Condition  \n0                      Leukemia  \n1         Endometrial Neoplasms  \n2                      Melanoma  \n3             Ovarian Neoplasms  \n4          Colorectal Neoplasms  \n...                         ...  \n13743          Breast Neoplasms  \n13744            Lung Neoplasms  \n13745        Huntington Disease  \n13746                 Hepatitis  \n13747  Muscular Atrophy, Spinal  \n\n[13748 rows x 11 columns]","text/html":"<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>index</th>\n      <th>NCT</th>\n      <th>Sponsor</th>\n      <th>Title</th>\n      <th>Summary</th>\n      <th>Start_Year</th>\n      <th>Start_Month</th>\n      <th>Phase</th>\n      <th>Enrollment</th>\n      <th>Status</th>\n      <th>Condition</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>0</td>\n      <td>NCT00003305</td>\n      <td>Sanofi</td>\n      <td>A Phase II Trial of Aminopterin in Adults and ...</td>\n      <td>RATIONALE: Drugs used in chemotherapy use diff...</td>\n      <td>1997</td>\n      <td>7</td>\n      <td>Phase 2</td>\n      <td>75</td>\n      <td>Completed</td>\n      <td>Leukemia</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>1</td>\n      <td>NCT00003821</td>\n      <td>Sanofi</td>\n      <td>Phase II Trial of Aminopterin in Patients With...</td>\n      <td>RATIONALE: Drugs used in chemotherapy use diff...</td>\n      <td>1998</td>\n      <td>1</td>\n      <td>Phase 2</td>\n      <td>0</td>\n      <td>Withdrawn</td>\n      <td>Endometrial Neoplasms</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>2</td>\n      <td>NCT00004025</td>\n      <td>Sanofi</td>\n      <td>Phase I/II Trial of the Safety, Immunogenicity...</td>\n      <td>RATIONALE: Vaccines made from a person's white...</td>\n      <td>1999</td>\n      <td>3</td>\n      <td>Phase 1/Phase 2</td>\n      <td>36</td>\n      <td>Unknown status</td>\n      <td>Melanoma</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>3</td>\n      <td>NCT00005645</td>\n      <td>Sanofi</td>\n      <td>Phase II Trial of ILX295501 Administered Orall...</td>\n      <td>RATIONALE: Drugs used in chemotherapy use diff...</td>\n      <td>1999</td>\n      <td>5</td>\n      <td>Phase 2</td>\n      <td>0</td>\n      <td>Withdrawn</td>\n      <td>Ovarian Neoplasms</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>4</td>\n      <td>NCT00008281</td>\n      <td>Sanofi</td>\n      <td>A Multicenter, Open-Label, Randomized, Three-A...</td>\n      <td>RATIONALE: Drugs used in chemotherapy use diff...</td>\n      <td>2000</td>\n      <td>10</td>\n      <td>Phase 3</td>\n      <td>0</td>\n      <td>Unknown status</td>\n      <td>Colorectal Neoplasms</td>\n    </tr>\n    <tr>\n      <th>...</th>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n    </tr>\n    <tr>\n      <th>13743</th>\n      <td>13743</td>\n      <td>NCT03726879</td>\n      <td>Roche</td>\n      <td>A Phase III, Randomized, Double-Blind, Placebo...</td>\n      <td>This study (also known as IMpassion050) will e...</td>\n      <td>2018</td>\n      <td>12</td>\n      <td>Phase 3</td>\n      <td>224</td>\n      <td>Recruiting</td>\n      <td>Breast Neoplasms</td>\n    </tr>\n    <tr>\n      <th>13744</th>\n      <td>13744</td>\n      <td>NCT03735121</td>\n      <td>Roche</td>\n      <td>A Two-Part Phase Ib/II Study to Investigate th...</td>\n      <td>This study will evaluate the pharmacokinetics,...</td>\n      <td>2018</td>\n      <td>12</td>\n      <td>Phase 1</td>\n      <td>245</td>\n      <td>Recruiting</td>\n      <td>Lung Neoplasms</td>\n    </tr>\n    <tr>\n      <th>13745</th>\n      <td>13745</td>\n      <td>NCT03761849</td>\n      <td>Roche</td>\n      <td>A Randomized, Multicenter, Double-Blind, Place...</td>\n      <td>This study will evaluate the efficacy, safety,...</td>\n      <td>2018</td>\n      <td>12</td>\n      <td>Phase 3</td>\n      <td>660</td>\n      <td>Not yet recruiting</td>\n      <td>Huntington Disease</td>\n    </tr>\n    <tr>\n      <th>13746</th>\n      <td>13746</td>\n      <td>NCT03762681</td>\n      <td>Roche</td>\n      <td>A Randomized, Placebo-controlled,Observer-blin...</td>\n      <td>This study is designed to assess the safety, t...</td>\n      <td>2018</td>\n      <td>12</td>\n      <td>Phase 1</td>\n      <td>75</td>\n      <td>Not yet recruiting</td>\n      <td>Hepatitis</td>\n    </tr>\n    <tr>\n      <th>13747</th>\n      <td>13747</td>\n      <td>NCT03779334</td>\n      <td>Roche</td>\n      <td>An Open-Label Study of Risdiplam in Infants Wi...</td>\n      <td>A global study of oral risdiplam in pre-sympto...</td>\n      <td>2019</td>\n      <td>2</td>\n      <td>Phase 2</td>\n      <td>25</td>\n      <td>Not yet recruiting</td>\n      <td>Muscular Atrophy, Spinal</td>\n    </tr>\n  </tbody>\n</table>\n<p>13748 rows × 11 columns</p>\n</div>"},"metadata":{}}],"execution_count":4},{"cell_type":"code","source":"trial_info.describe(include='all')","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:11:45.020661Z","iopub.execute_input":"2025-11-13T14:11:45.021192Z","iopub.status.idle":"2025-11-13T14:11:45.079649Z","shell.execute_reply.started":"2025-11-13T14:11:45.021165Z","shell.execute_reply":"2025-11-13T14:11:45.078901Z"}},"outputs":[{"name":"stderr","text":"/usr/local/lib/python3.11/dist-packages/pandas/io/formats/format.py:1458: RuntimeWarning: invalid value encountered in greater\n  has_large_values = (abs_vals > 1e6).any()\n/usr/local/lib/python3.11/dist-packages/pandas/io/formats/format.py:1459: RuntimeWarning: invalid value encountered in less\n  has_small_values = ((abs_vals < 10 ** (-self.digits)) & (abs_vals > 0)).any()\n/usr/local/lib/python3.11/dist-packages/pandas/io/formats/format.py:1459: RuntimeWarning: invalid value encountered in greater\n  has_small_values = ((abs_vals < 10 ** (-self.digits)) & (abs_vals > 0)).any()\n","output_type":"stream"},{"execution_count":5,"output_type":"execute_result","data":{"text/plain":"               index          NCT Sponsor                    Title Summary  \\\ncount   13748.000000        13748   13748                    13604   13748   \nunique           NaN        13748      10                    13434   13565   \ntop              NaN  NCT03779334     GSK  Human Photoallergy Test  #NAME?   \nfreq             NaN            1    2473                        7      11   \nmean     6873.500000          NaN     NaN                      NaN     NaN   \nstd      3968.850085          NaN     NaN                      NaN     NaN   \nmin         0.000000          NaN     NaN                      NaN     NaN   \n25%      3436.750000          NaN     NaN                      NaN     NaN   \n50%      6873.500000          NaN     NaN                      NaN     NaN   \n75%     10310.250000          NaN     NaN                      NaN     NaN   \nmax     13747.000000          NaN     NaN                      NaN     NaN   \n\n          Start_Year   Start_Month    Phase    Enrollment     Status  \\\ncount   13748.000000  13748.000000    13485  13748.000000      13748   \nunique           NaN           NaN        7           NaN          9   \ntop              NaN           NaN  Phase 3           NaN  Completed   \nfreq             NaN           NaN     4887           NaN      10568   \nmean     2009.155586      6.691155      NaN    440.783678        NaN   \nstd         4.797615      3.486359      NaN   1944.530768        NaN   \nmin      1984.000000      1.000000      NaN      0.000000        NaN   \n25%      2006.000000      4.000000      NaN     40.000000        NaN   \n50%      2009.000000      7.000000      NaN    124.000000        NaN   \n75%      2013.000000     10.000000      NaN    365.000000        NaN   \nmax      2020.000000     12.000000      NaN  84496.000000        NaN   \n\n                        Condition  \ncount                       13748  \nunique                        867  \ntop     Diabetes Mellitus, Type 2  \nfreq                          536  \nmean                          NaN  \nstd                           NaN  \nmin                           NaN  \n25%                           NaN  \n50%                           NaN  \n75%                           NaN  \nmax                           NaN  ","text/html":"<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>index</th>\n      <th>NCT</th>\n      <th>Sponsor</th>\n      <th>Title</th>\n      <th>Summary</th>\n      <th>Start_Year</th>\n      <th>Start_Month</th>\n      <th>Phase</th>\n      <th>Enrollment</th>\n      <th>Status</th>\n      <th>Condition</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>count</th>\n      <td>13748.000000</td>\n      <td>13748</td>\n      <td>13748</td>\n      <td>13604</td>\n      <td>13748</td>\n      <td>13748.000000</td>\n      <td>13748.000000</td>\n      <td>13485</td>\n      <td>13748.000000</td>\n      <td>13748</td>\n      <td>13748</td>\n    </tr>\n    <tr>\n      <th>unique</th>\n      <td>NaN</td>\n      <td>13748</td>\n      <td>10</td>\n      <td>13434</td>\n      <td>13565</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>7</td>\n      <td>NaN</td>\n      <td>9</td>\n      <td>867</td>\n    </tr>\n    <tr>\n      <th>top</th>\n      <td>NaN</td>\n      <td>NCT03779334</td>\n      <td>GSK</td>\n      <td>Human Photoallergy Test</td>\n      <td>#NAME?</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>Phase 3</td>\n      <td>NaN</td>\n      <td>Completed</td>\n      <td>Diabetes Mellitus, Type 2</td>\n    </tr>\n    <tr>\n      <th>freq</th>\n      <td>NaN</td>\n      <td>1</td>\n      <td>2473</td>\n      <td>7</td>\n      <td>11</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>4887</td>\n      <td>NaN</td>\n      <td>10568</td>\n      <td>536</td>\n    </tr>\n    <tr>\n      <th>mean</th>\n      <td>6873.500000</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>2009.155586</td>\n      <td>6.691155</td>\n      <td>NaN</td>\n      <td>440.783678</td>\n      <td>NaN</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>std</th>\n      <td>3968.850085</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>4.797615</td>\n      <td>3.486359</td>\n      <td>NaN</td>\n      <td>1944.530768</td>\n      <td>NaN</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>min</th>\n      <td>0.000000</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>1984.000000</td>\n      <td>1.000000</td>\n      <td>NaN</td>\n      <td>0.000000</td>\n      <td>NaN</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>25%</th>\n      <td>3436.750000</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>2006.000000</td>\n      <td>4.000000</td>\n      <td>NaN</td>\n      <td>40.000000</td>\n      <td>NaN</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>50%</th>\n      <td>6873.500000</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>2009.000000</td>\n      <td>7.000000</td>\n      <td>NaN</td>\n      <td>124.000000</td>\n      <td>NaN</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>75%</th>\n      <td>10310.250000</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>2013.000000</td>\n      <td>10.000000</td>\n      <td>NaN</td>\n      <td>365.000000</td>\n      <td>NaN</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>max</th>\n      <td>13747.000000</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>2020.000000</td>\n      <td>12.000000</td>\n      <td>NaN</td>\n      <td>84496.000000</td>\n      <td>NaN</td>\n      <td>NaN</td>\n    </tr>\n  </tbody>\n</table>\n</div>"},"metadata":{}}],"execution_count":5},{"cell_type":"code","source":"def get_sorted_counts(df, group_by):\n    return df[group_by].value_counts(ascending=False).reset_index()\n    \nprint(f\"Distribution of Sponsors:\\n{get_sorted_counts(trial_info, 'Sponsor')}\")\nprint(f\"\\nDistribution of Phases:\\n{get_sorted_counts(trial_info, 'Phase')}\")\nprint(f\"\\nDistribution of Statuses:\\n{get_sorted_counts(trial_info, 'Status')}\")\nprint(f\"\\nDistribution of Conditions Targeted By Trial:\\n{get_sorted_counts(trial_info, 'Condition')}\")","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:11:45.080448Z","iopub.execute_input":"2025-11-13T14:11:45.080711Z","iopub.status.idle":"2025-11-13T14:11:45.097745Z","shell.execute_reply.started":"2025-11-13T14:11:45.080683Z","shell.execute_reply":"2025-11-13T14:11:45.096882Z"}},"outputs":[{"name":"stdout","text":"Distribution of Sponsors:\n    Sponsor  count\n0       GSK   2473\n1  Novartis   2320\n2    Pfizer   1970\n3     Merck   1770\n4    Sanofi   1524\n5       JNJ   1143\n6     Roche   1095\n7     Bayer    619\n8    AbbVie    417\n9    Gilead    417\n\nDistribution of Phases:\n             Phase  count\n0          Phase 3   4887\n1          Phase 2   3596\n2          Phase 1   2516\n3          Phase 4   2015\n4  Phase 1/Phase 2    322\n5  Phase 2/Phase 3    139\n6    Early Phase 1     10\n\nDistribution of Statuses:\n                    Status  count\n0                Completed  10568\n1               Terminated   1285\n2               Recruiting    800\n3   Active, not recruiting    646\n4                Withdrawn    291\n5       Not yet recruiting    108\n6           Unknown status     19\n7                Suspended     16\n8  Enrolling by invitation     15\n\nDistribution of Conditions Targeted By Trial:\n                                  Condition  count\n0                 Diabetes Mellitus, Type 2    536\n1                          Breast Neoplasms    388\n2    Pulmonary Disease, Chronic Obstructive    339\n3                              Hypertension    338\n4                                    Asthma    334\n..                                      ...    ...\n862                         Wound Infection      1\n863                     Neural Tube Defects      1\n864                     Hyperparathyroidism      1\n865                    Pyoderma Gangrenosum      1\n866                              Foot Ulcer      1\n\n[867 rows x 2 columns]\n","output_type":"stream"}],"execution_count":6},{"cell_type":"markdown","source":"...so the target variable here is `Status`. This is a very unbalanced class with the majority of examples (77%) having a `Completed` Status (which I guess will represent the 'Successful' class of our target). The 'Unsuccessful' class will be represented by the `Terminated` + `Withdrawn` + `Suspended` examples. All of the rest will be discarded, under the assumption that they are ongoing (e.g. still recruiting), so their success/failure is unknown at this time.  ","metadata":{}},{"cell_type":"markdown","source":"## Creating the Input and Target Features","metadata":{}},{"cell_type":"code","source":"statuses = ['Completed', 'Terminated', 'Withdrawn', 'Suspended']\ntrial_info = trial_info[trial_info['Status'].isin(statuses)]\ntrial_info.head()","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:11:45.098551Z","iopub.execute_input":"2025-11-13T14:11:45.099293Z","iopub.status.idle":"2025-11-13T14:11:45.123468Z","shell.execute_reply.started":"2025-11-13T14:11:45.099267Z","shell.execute_reply":"2025-11-13T14:11:45.122894Z"}},"outputs":[{"execution_count":7,"output_type":"execute_result","data":{"text/plain":"   index          NCT Sponsor  \\\n0      0  NCT00003305  Sanofi   \n1      1  NCT00003821  Sanofi   \n3      3  NCT00005645  Sanofi   \n6      6  NCT00012389  Sanofi   \n7      7  NCT00017459  Sanofi   \n\n                                               Title  \\\n0  A Phase II Trial of Aminopterin in Adults and ...   \n1  Phase II Trial of Aminopterin in Patients With...   \n3  Phase II Trial of ILX295501 Administered Orall...   \n6  A Multicenter, Open-Label, Randomized, Two-Arm...   \n7  The International Tirazone Triple Trial (i3T):...   \n\n                                             Summary  Start_Year  Start_Month  \\\n0  RATIONALE: Drugs used in chemotherapy use diff...        1997            7   \n1  RATIONALE: Drugs used in chemotherapy use diff...        1998            1   \n3  RATIONALE: Drugs used in chemotherapy use diff...        1999            5   \n6  RATIONALE: Drugs used in chemotherapy use diff...        2000           12   \n7  RATIONALE: Drugs used in chemotherapy use diff...        2000            7   \n\n     Phase  Enrollment     Status                       Condition  \n0  Phase 2          75  Completed                        Leukemia  \n1  Phase 2           0  Withdrawn           Endometrial Neoplasms  \n3  Phase 2           0  Withdrawn               Ovarian Neoplasms  \n6  Phase 3           0  Completed            Colorectal Neoplasms  \n7  Phase 3           0  Completed  Carcinoma, Non-Small-Cell Lung  ","text/html":"<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>index</th>\n      <th>NCT</th>\n      <th>Sponsor</th>\n      <th>Title</th>\n      <th>Summary</th>\n      <th>Start_Year</th>\n      <th>Start_Month</th>\n      <th>Phase</th>\n      <th>Enrollment</th>\n      <th>Status</th>\n      <th>Condition</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>0</td>\n      <td>NCT00003305</td>\n      <td>Sanofi</td>\n      <td>A Phase II Trial of Aminopterin in Adults and ...</td>\n      <td>RATIONALE: Drugs used in chemotherapy use diff...</td>\n      <td>1997</td>\n      <td>7</td>\n      <td>Phase 2</td>\n      <td>75</td>\n      <td>Completed</td>\n      <td>Leukemia</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>1</td>\n      <td>NCT00003821</td>\n      <td>Sanofi</td>\n      <td>Phase II Trial of Aminopterin in Patients With...</td>\n      <td>RATIONALE: Drugs used in chemotherapy use diff...</td>\n      <td>1998</td>\n      <td>1</td>\n      <td>Phase 2</td>\n      <td>0</td>\n      <td>Withdrawn</td>\n      <td>Endometrial Neoplasms</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>3</td>\n      <td>NCT00005645</td>\n      <td>Sanofi</td>\n      <td>Phase II Trial of ILX295501 Administered Orall...</td>\n      <td>RATIONALE: Drugs used in chemotherapy use diff...</td>\n      <td>1999</td>\n      <td>5</td>\n      <td>Phase 2</td>\n      <td>0</td>\n      <td>Withdrawn</td>\n      <td>Ovarian Neoplasms</td>\n    </tr>\n    <tr>\n      <th>6</th>\n      <td>6</td>\n      <td>NCT00012389</td>\n      <td>Sanofi</td>\n      <td>A Multicenter, Open-Label, Randomized, Two-Arm...</td>\n      <td>RATIONALE: Drugs used in chemotherapy use diff...</td>\n      <td>2000</td>\n      <td>12</td>\n      <td>Phase 3</td>\n      <td>0</td>\n      <td>Completed</td>\n      <td>Colorectal Neoplasms</td>\n    </tr>\n    <tr>\n      <th>7</th>\n      <td>7</td>\n      <td>NCT00017459</td>\n      <td>Sanofi</td>\n      <td>The International Tirazone Triple Trial (i3T):...</td>\n      <td>RATIONALE: Drugs used in chemotherapy use diff...</td>\n      <td>2000</td>\n      <td>7</td>\n      <td>Phase 3</td>\n      <td>0</td>\n      <td>Completed</td>\n      <td>Carcinoma, Non-Small-Cell Lung</td>\n    </tr>\n  </tbody>\n</table>\n</div>"},"metadata":{}}],"execution_count":7},{"cell_type":"markdown","source":"Okay, so now we have filtered the dataset to only contain records that have the statuses that we can interpret in terms of success. Next, let's create a new column, `Success`, that is a binary value representing whether the trial was successful (1) i.e. it completed, or unsuccessful (0) i.e. it did not complete. ","metadata":{}},{"cell_type":"code","source":"def status_to_success(status):\n    return 1 if status == 'Completed' else 0 \n\ntrial_info['Success'] = trial_info['Status'].apply(status_to_success)\ntrial_info['Success'] = trial_info['Success'].astype(float)\ntrial_info.head()","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:11:45.124160Z","iopub.execute_input":"2025-11-13T14:11:45.124385Z","iopub.status.idle":"2025-11-13T14:11:45.140232Z","shell.execute_reply.started":"2025-11-13T14:11:45.124366Z","shell.execute_reply":"2025-11-13T14:11:45.139473Z"}},"outputs":[{"name":"stderr","text":"/tmp/ipykernel_950/2197835071.py:4: SettingWithCopyWarning: \nA value is trying to be set on a copy of a slice from a DataFrame.\nTry using .loc[row_indexer,col_indexer] = value instead\n\nSee the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n  trial_info['Success'] = trial_info['Status'].apply(status_to_success)\n/tmp/ipykernel_950/2197835071.py:5: SettingWithCopyWarning: \nA value is trying to be set on a copy of a slice from a DataFrame.\nTry using .loc[row_indexer,col_indexer] = value instead\n\nSee the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n  trial_info['Success'] = trial_info['Success'].astype(float)\n","output_type":"stream"},{"execution_count":8,"output_type":"execute_result","data":{"text/plain":"   index          NCT Sponsor  \\\n0      0  NCT00003305  Sanofi   \n1      1  NCT00003821  Sanofi   \n3      3  NCT00005645  Sanofi   \n6      6  NCT00012389  Sanofi   \n7      7  NCT00017459  Sanofi   \n\n                                               Title  \\\n0  A Phase II Trial of Aminopterin in Adults and ...   \n1  Phase II Trial of Aminopterin in Patients With...   \n3  Phase II Trial of ILX295501 Administered Orall...   \n6  A Multicenter, Open-Label, Randomized, Two-Arm...   \n7  The International Tirazone Triple Trial (i3T):...   \n\n                                             Summary  Start_Year  Start_Month  \\\n0  RATIONALE: Drugs used in chemotherapy use diff...        1997            7   \n1  RATIONALE: Drugs used in chemotherapy use diff...        1998            1   \n3  RATIONALE: Drugs used in chemotherapy use diff...        1999            5   \n6  RATIONALE: Drugs used in chemotherapy use diff...        2000           12   \n7  RATIONALE: Drugs used in chemotherapy use diff...        2000            7   \n\n     Phase  Enrollment     Status                       Condition  Success  \n0  Phase 2          75  Completed                        Leukemia      1.0  \n1  Phase 2           0  Withdrawn           Endometrial Neoplasms      0.0  \n3  Phase 2           0  Withdrawn               Ovarian Neoplasms      0.0  \n6  Phase 3           0  Completed            Colorectal Neoplasms      1.0  \n7  Phase 3           0  Completed  Carcinoma, Non-Small-Cell Lung      1.0  ","text/html":"<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>index</th>\n      <th>NCT</th>\n      <th>Sponsor</th>\n      <th>Title</th>\n      <th>Summary</th>\n      <th>Start_Year</th>\n      <th>Start_Month</th>\n      <th>Phase</th>\n      <th>Enrollment</th>\n      <th>Status</th>\n      <th>Condition</th>\n      <th>Success</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>0</td>\n      <td>NCT00003305</td>\n      <td>Sanofi</td>\n      <td>A Phase II Trial of Aminopterin in Adults and ...</td>\n      <td>RATIONALE: Drugs used in chemotherapy use diff...</td>\n      <td>1997</td>\n      <td>7</td>\n      <td>Phase 2</td>\n      <td>75</td>\n      <td>Completed</td>\n      <td>Leukemia</td>\n      <td>1.0</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>1</td>\n      <td>NCT00003821</td>\n      <td>Sanofi</td>\n      <td>Phase II Trial of Aminopterin in Patients With...</td>\n      <td>RATIONALE: Drugs used in chemotherapy use diff...</td>\n      <td>1998</td>\n      <td>1</td>\n      <td>Phase 2</td>\n      <td>0</td>\n      <td>Withdrawn</td>\n      <td>Endometrial Neoplasms</td>\n      <td>0.0</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>3</td>\n      <td>NCT00005645</td>\n      <td>Sanofi</td>\n      <td>Phase II Trial of ILX295501 Administered Orall...</td>\n      <td>RATIONALE: Drugs used in chemotherapy use diff...</td>\n      <td>1999</td>\n      <td>5</td>\n      <td>Phase 2</td>\n      <td>0</td>\n      <td>Withdrawn</td>\n      <td>Ovarian Neoplasms</td>\n      <td>0.0</td>\n    </tr>\n    <tr>\n      <th>6</th>\n      <td>6</td>\n      <td>NCT00012389</td>\n      <td>Sanofi</td>\n      <td>A Multicenter, Open-Label, Randomized, Two-Arm...</td>\n      <td>RATIONALE: Drugs used in chemotherapy use diff...</td>\n      <td>2000</td>\n      <td>12</td>\n      <td>Phase 3</td>\n      <td>0</td>\n      <td>Completed</td>\n      <td>Colorectal Neoplasms</td>\n      <td>1.0</td>\n    </tr>\n    <tr>\n      <th>7</th>\n      <td>7</td>\n      <td>NCT00017459</td>\n      <td>Sanofi</td>\n      <td>The International Tirazone Triple Trial (i3T):...</td>\n      <td>RATIONALE: Drugs used in chemotherapy use diff...</td>\n      <td>2000</td>\n      <td>7</td>\n      <td>Phase 3</td>\n      <td>0</td>\n      <td>Completed</td>\n      <td>Carcinoma, Non-Small-Cell Lung</td>\n      <td>1.0</td>\n    </tr>\n  </tbody>\n</table>\n</div>"},"metadata":{}}],"execution_count":8},{"cell_type":"code","source":"print(f\"Total number of examples remaining:\\n{len(trial_info)}\")\nprint(f\"\\nDistribution of Success/Failure:\\n{get_sorted_counts(trial_info, 'Success')}\")","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:11:45.141029Z","iopub.execute_input":"2025-11-13T14:11:45.141545Z","iopub.status.idle":"2025-11-13T14:11:45.156181Z","shell.execute_reply.started":"2025-11-13T14:11:45.141525Z","shell.execute_reply":"2025-11-13T14:11:45.155477Z"}},"outputs":[{"name":"stdout","text":"Total number of examples remaining:\n12160\n\nDistribution of Success/Failure:\n   Success  count\n0      1.0  10568\n1      0.0   1592\n","output_type":"stream"}],"execution_count":9},{"cell_type":"markdown","source":"Note that there is still a significant class imbalance between success (1; 87%) and unsuccessful (0; 13%). We will need to address this during training and when splitting the data into training, validation and test sets.","metadata":{}},{"cell_type":"code","source":"trial_info['input'] = 'TITLE: ' + trial_info.Title + '; SUMMARY: ' + trial_info.Summary + '; PHASE: ' + trial_info.Phase","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:11:45.157091Z","iopub.execute_input":"2025-11-13T14:11:45.157327Z","iopub.status.idle":"2025-11-13T14:11:45.206736Z","shell.execute_reply.started":"2025-11-13T14:11:45.157308Z","shell.execute_reply":"2025-11-13T14:11:45.205810Z"}},"outputs":[{"name":"stderr","text":"/tmp/ipykernel_950/175036437.py:1: SettingWithCopyWarning: \nA value is trying to be set on a copy of a slice from a DataFrame.\nTry using .loc[row_indexer,col_indexer] = value instead\n\nSee the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n  trial_info['input'] = 'TITLE: ' + trial_info.Title + '; SUMMARY: ' + trial_info.Summary + '; PHASE: ' + trial_info.Phase\n","output_type":"stream"}],"execution_count":10},{"cell_type":"code","source":"for text in trial_info.input.sample(10):\n    print(text, end=\"\\n\\n\")","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:11:45.208709Z","iopub.execute_input":"2025-11-13T14:11:45.208940Z","iopub.status.idle":"2025-11-13T14:11:45.214271Z","shell.execute_reply.started":"2025-11-13T14:11:45.208923Z","shell.execute_reply":"2025-11-13T14:11:45.213471Z"}},"outputs":[{"name":"stdout","text":"TITLE: Safety and Immunogenicity of Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age; SUMMARY: This study will assess safety and immunogenicity of GSK Biologicals' H5N1 flu candidate vaccine GSK1557484A in children 6 months to < 18 years of age.; PHASE: Phase 3\n\nTITLE: A Single Centre, Open Label Study to Characterize the PK-PDE10A Enzyme Occupancy Relationship of RO5545965 After a Single Dose in Healthy Male Volunteers Using [11C]IMA107 Positron Emission Tomography; SUMMARY: This single center, open-label study will evaluate the PK-PDE10A Enzyme Occupancy Relationship of RO5545965 after a single dose in healthy male volunteers by positron emission tomography (PET).; PHASE: Phase 1\n\nTITLE: An Open-label Repeat Dosing Study of Eltrombopag Olamine (SB-497115-GR) in Adult Subjects, With Chronic Idiopathic Thrombocytopenic Purpura (ITP); SUMMARY: This open-label, repeat dosing study, TRA108057, will evaluate the efficacy, safety and tolerability of eltrombopag, when administered in a repeat, cyclic dosing schedule. The study will describe the effect of repeated (3 cycles), intermittent dosing of eltrombopag on the pharmacodynamics and durability of eltrombopag response as measured by the peripheral platelet counts. For more information or to see if you qualify, please visit: http://www.itpstudy.com/gov; PHASE: Phase 2\n\nTITLE: A Randomized, Blinded, Placebo-Controlled, Dose Finding Study to Assess the Safety and Efficacy of the Oral Thrombopoietin Receptor Agonist, Eltrombopag, Administered to Subjects With Acute Myelogenous Leukaemia (AML) Receiving Induction Chemotherapy; SUMMARY: The purpose of this randomized, blinded, placebo-controlled study is to provide clinical safety and exploratory efficacy data on the use of Eltrombopag in adult subjects with Acute Myeloid Leukemia (AML) receiving standard induction chemotherapy with daunorubicin plus cytarabine. These safety data are considered necessary to further development of Eltrombopag in both adult and paediatric patients suffering from malignant diseases with secondary thrombocytopenia. A minimum of 120 evaluable subjects with newly diagnosed with AML will be stratified by antecedent malignant hematologic disorder and age.; PHASE: Phase 2\n\nTITLE: A Single Arm, Open-label, Multicenter Study Evaluating the Long-term Safety and Tolerability of 0.5 mg Fingolimod (FTY720) Administered Orally Once Daily in Patients With Relapsing Forms of Multiple Sclerosis; SUMMARY: The purpose of this study is to collect long-term safety and tolerability, long-term efficacy, and health outcome data in all patients currently ongoing in the fingolimod multiple sclerosis clinical development program. This study will combine all currently ongoing Phase II and III fingolimod extension studies as well as ongoing and newly planned studies into one single long-term extension protocol that will provide patients with continuous treatment and will continue until fingolimod is registered, commercially available, and reimbursed in the respective countries.; PHASE: Phase 3\n\nTITLE: A Phase II, Open-label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti‚àíPD-L1 Antibody) Compared With Docetaxel in Patients With Non‚àíSmall Cell Lung Cancer After Platinum Failure; SUMMARY: This multicenter, open-label, randomized study will evaluate the efficacy and safety of Atezolizumab compared with docetaxel in participants with advanced or metastatic non-small cell lung cancer after platinum failure. Participants will be randomized to receive either Atezolizumab 1200 milligram (mg) intravenously every 3 weeks or docetaxel 75 milligram per meter square (mg/m^2) intravenously every 3 weeks. Treatment with Atezolizumab may be continued as long as participants are experiencing clinical benefit as assessed by the investigator, i.e., in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression.; PHASE: Phase 2\n\nTITLE: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Nasal Spray for 2 Weeks in Chinese Adult and Adolescent Subjects With Allergic Rhinitis; SUMMARY: The objective of this study is to compare the efficacy and safety of Fluticasone Furoate Nasal Spray (FFNS), that is FFNS with placebo in Chinese adult and adolescent subjects with Allergic Rhinitis as AR. There are 3 phases, 2 to14 day run in, 2 week treatment, and 3 to 5 day follow up. After run in period, at least 360 subjects with AR ( ages of 12yrs and 65yrs, inclusive) will be randomised to receive FFNS 110ug once daily or placebo for 2 weeks. The primary endpoint is the change from baseline of reflective total nasal symptom score (rTNSS) during treatment period, and the secondary endpoints include mean change from baseline in nasal finding scores by rhinoscopy at completion of study treatment, and severity of overall inference in activities of daily living. Safety measures include AE (Adverse Event) reports, ECGs (Electrocardiograph), physical exams, vital signs, and nasal exam. In addition, reflective total ocular symptom score (rTOSS) will be measured as an explorative endpoint, only in the specific AR (Allergic Rhinitis) patients with severe ocular symptoms.; PHASE: Phase 3\n\nTITLE: A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Evaluating the Efficacy and Safety of Three Doses of SAR236553 (REGN727) Over 12 Weeks in Patients With Primary Hypercholesterolemia and LDL-cholesterol ‚â•100 mg/dL (‚â•2.59 mmol/L) on Ongoing Stable Atorvastatin Therapy; SUMMARY: Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9). Primary Objective of the study: To evaluate the effect of alirocumab on low-density lipoprotein cholesterol (LDL-C) levels after 12 weeks of treatment in comparison with placebo in participants with LDL-C ‚â•100 mg/dL (‚â•2.59 mmol/L) on ongoing stable atorvastatin therapy. Secondary Objectives: - To evaluate the effects of alirocumab on other lipid levels after 12 weeks of treatment in comparison with placebo - To evaluate the safety and tolerability of alirocumab - To evaluate the development of anti-alirocumab antibodies - To evaluate the pharmacokinetics of alirocumab; PHASE: Phase 2\n\nTITLE: A Multicenter, Randomized, Parallel-group, 4-Week, Double-Blind and Active Comparator-Controlled Study to Assess Efficacy, Safety, and Tolerability of Etoricoxib 60 mg Once Daily Versus Diclofenac Sodium 75 mg Twice Daily in the Treatment of Chinese Patients With Osteoarthritis of the Knee or Hip; SUMMARY: A Study to Assess Etoricoxib versus Diclofenac in Chinese Patients with Osteoarthritis of the Knee or Hip; PHASE: Phase 4\n\nTITLE: A Randomized, Double-blind, Placebo-controlled, 2-period, Cross-over Study to Assess the Efficacy and Safety of Differing Doses of NVA237 Administered Either Once Daily or Twice Daily, in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD); SUMMARY: This study was designed to investigate the efficacy and safety of NVA237, a long-acting muscarinic antagonist, in patients with moderate to severe COPD.; PHASE: Phase 2\n\n","output_type":"stream"}],"execution_count":11},{"cell_type":"code","source":"# Remove any values from 'input' feature that are nan\ndata = trial_info.dropna(subset=[\"input\"])\nlen(data)","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:11:45.215031Z","iopub.execute_input":"2025-11-13T14:11:45.215269Z","iopub.status.idle":"2025-11-13T14:11:45.231630Z","shell.execute_reply.started":"2025-11-13T14:11:45.215253Z","shell.execute_reply":"2025-11-13T14:11:45.230907Z"}},"outputs":[{"execution_count":12,"output_type":"execute_result","data":{"text/plain":"11802"},"metadata":{}}],"execution_count":12},{"cell_type":"code","source":"data.describe()","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:11:45.275146Z","iopub.execute_input":"2025-11-13T14:11:45.275359Z","iopub.status.idle":"2025-11-13T14:11:45.294532Z","shell.execute_reply.started":"2025-11-13T14:11:45.275341Z","shell.execute_reply":"2025-11-13T14:11:45.293914Z"}},"outputs":[{"execution_count":13,"output_type":"execute_result","data":{"text/plain":"              index    Start_Year   Start_Month    Enrollment       Success\ncount  11802.000000  11802.000000  11802.000000  11802.000000  11802.000000\nmean    6669.111845   2008.257753      6.648365    429.082867      0.869259\nstd     3918.216037      4.269221      3.488122   1872.177639      0.337131\nmin        0.000000   1984.000000      1.000000      0.000000      0.000000\n25%     3199.250000   2005.000000      4.000000     37.000000      1.000000\n50%     6729.000000   2008.000000      7.000000    120.000000      1.000000\n75%     9953.750000   2011.000000     10.000000    360.000000      1.000000\nmax    13740.000000   2019.000000     12.000000  84496.000000      1.000000","text/html":"<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>index</th>\n      <th>Start_Year</th>\n      <th>Start_Month</th>\n      <th>Enrollment</th>\n      <th>Success</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>count</th>\n      <td>11802.000000</td>\n      <td>11802.000000</td>\n      <td>11802.000000</td>\n      <td>11802.000000</td>\n      <td>11802.000000</td>\n    </tr>\n    <tr>\n      <th>mean</th>\n      <td>6669.111845</td>\n      <td>2008.257753</td>\n      <td>6.648365</td>\n      <td>429.082867</td>\n      <td>0.869259</td>\n    </tr>\n    <tr>\n      <th>std</th>\n      <td>3918.216037</td>\n      <td>4.269221</td>\n      <td>3.488122</td>\n      <td>1872.177639</td>\n      <td>0.337131</td>\n    </tr>\n    <tr>\n      <th>min</th>\n      <td>0.000000</td>\n      <td>1984.000000</td>\n      <td>1.000000</td>\n      <td>0.000000</td>\n      <td>0.000000</td>\n    </tr>\n    <tr>\n      <th>25%</th>\n      <td>3199.250000</td>\n      <td>2005.000000</td>\n      <td>4.000000</td>\n      <td>37.000000</td>\n      <td>1.000000</td>\n    </tr>\n    <tr>\n      <th>50%</th>\n      <td>6729.000000</td>\n      <td>2008.000000</td>\n      <td>7.000000</td>\n      <td>120.000000</td>\n      <td>1.000000</td>\n    </tr>\n    <tr>\n      <th>75%</th>\n      <td>9953.750000</td>\n      <td>2011.000000</td>\n      <td>10.000000</td>\n      <td>360.000000</td>\n      <td>1.000000</td>\n    </tr>\n    <tr>\n      <th>max</th>\n      <td>13740.000000</td>\n      <td>2019.000000</td>\n      <td>12.000000</td>\n      <td>84496.000000</td>\n      <td>1.000000</td>\n    </tr>\n  </tbody>\n</table>\n</div>"},"metadata":{}}],"execution_count":13},{"cell_type":"markdown","source":"## Tokenisation and Numericalisation\n\nTransformers uses a Dataset object for storing a... well a dataset, of course! We can create one like so:","metadata":{}},{"cell_type":"code","source":"from datasets import Dataset,DatasetDict","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:11:45.397343Z","iopub.execute_input":"2025-11-13T14:11:45.398074Z","iopub.status.idle":"2025-11-13T14:11:45.978592Z","shell.execute_reply.started":"2025-11-13T14:11:45.398021Z","shell.execute_reply":"2025-11-13T14:11:45.977973Z"}},"outputs":[],"execution_count":14},{"cell_type":"code","source":"ds = Dataset.from_pandas(data)\nds","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:11:45.979660Z","iopub.execute_input":"2025-11-13T14:11:45.980144Z","iopub.status.idle":"2025-11-13T14:11:46.152165Z","shell.execute_reply.started":"2025-11-13T14:11:45.980116Z","shell.execute_reply":"2025-11-13T14:11:46.151378Z"}},"outputs":[{"execution_count":15,"output_type":"execute_result","data":{"text/plain":"Dataset({\n    features: ['index', 'NCT', 'Sponsor', 'Title', 'Summary', 'Start_Year', 'Start_Month', 'Phase', 'Enrollment', 'Status', 'Condition', 'Success', 'input', '__index_level_0__'],\n    num_rows: 11802\n})"},"metadata":{}}],"execution_count":15},{"cell_type":"markdown","source":"But we can't pass the texts directly into a model. A deep learning model expects numbers as inputs, not English sentences! So we need to do two things:\n\n- *Tokenization*: Split each text up into words (or actually, as we'll see, into tokens)\n- *Numericalization*: Convert each word (or token) into a number.\n\nThe details about how this is done actually depend on the particular model we use. So first we'll need to pick a model. There are thousands of models available, but a reasonable starting point for nearly any NLP problem is to use this (replace \"small\" with \"large\" for a slower but more accurate model, once you've finished exploring):","metadata":{}},{"cell_type":"code","source":"# model_nm = 'microsoft/deberta-v3-small'\nmodel_nm = 'distilbert-base-uncased'","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:11:46.153105Z","iopub.execute_input":"2025-11-13T14:11:46.153463Z","iopub.status.idle":"2025-11-13T14:11:46.156961Z","shell.execute_reply.started":"2025-11-13T14:11:46.153435Z","shell.execute_reply":"2025-11-13T14:11:46.156198Z"}},"outputs":[],"execution_count":16},{"cell_type":"markdown","source":"`AutoTokenizer` will create a tokenizer appropriate for a given model:","metadata":{}},{"cell_type":"code","source":"from transformers import AutoModelForSequenceClassification,AutoTokenizer,DistilBertTokenizer, DistilBertForSequenceClassification,DataCollatorWithPadding\n# tokz = AutoTokenizer.from_pretrained(model_nm)\ntokz = DistilBertTokenizer.from_pretrained(model_nm)","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:11:46.158157Z","iopub.execute_input":"2025-11-13T14:11:46.158342Z","iopub.status.idle":"2025-11-13T14:11:54.986146Z","shell.execute_reply.started":"2025-11-13T14:11:46.158328Z","shell.execute_reply":"2025-11-13T14:11:54.985446Z"}},"outputs":[{"name":"stderr","text":"2025-11-13 14:11:49.983963: E external/local_xla/xla/stream_executor/cuda/cuda_fft.cc:477] Unable to register cuFFT factory: Attempting to register factory for plugin cuFFT when one has already been registered\nWARNING: All log messages before absl::InitializeLog() is called are written to STDERR\nE0000 00:00:1763043110.006907     950 cuda_dnn.cc:8310] Unable to register cuDNN factory: Attempting to register factory for plugin cuDNN when one has already been registered\nE0000 00:00:1763043110.013914     950 cuda_blas.cc:1418] Unable to register cuBLAS factory: Attempting to register factory for plugin cuBLAS when one has already been registered\n","output_type":"stream"},{"traceback":["\u001b[0;31m---------------------------------------------------------------------------\u001b[0m","\u001b[0;31mAttributeError\u001b[0m                            Traceback (most recent call last)","\u001b[0;31mAttributeError\u001b[0m: 'MessageFactory' object has no attribute 'GetPrototype'"],"ename":"AttributeError","evalue":"'MessageFactory' object has no attribute 'GetPrototype'","output_type":"error"},{"traceback":["\u001b[0;31m---------------------------------------------------------------------------\u001b[0m","\u001b[0;31mAttributeError\u001b[0m                            Traceback (most recent call last)","\u001b[0;31mAttributeError\u001b[0m: 'MessageFactory' object has no attribute 'GetPrototype'"],"ename":"AttributeError","evalue":"'MessageFactory' object has no attribute 'GetPrototype'","output_type":"error"},{"traceback":["\u001b[0;31m---------------------------------------------------------------------------\u001b[0m","\u001b[0;31mAttributeError\u001b[0m                            Traceback (most recent call last)","\u001b[0;31mAttributeError\u001b[0m: 'MessageFactory' object has no attribute 'GetPrototype'"],"ename":"AttributeError","evalue":"'MessageFactory' object has no attribute 'GetPrototype'","output_type":"error"},{"traceback":["\u001b[0;31m---------------------------------------------------------------------------\u001b[0m","\u001b[0;31mAttributeError\u001b[0m                            Traceback (most recent call last)","\u001b[0;31mAttributeError\u001b[0m: 'MessageFactory' object has no attribute 'GetPrototype'"],"ename":"AttributeError","evalue":"'MessageFactory' object has no attribute 'GetPrototype'","output_type":"error"},{"traceback":["\u001b[0;31m---------------------------------------------------------------------------\u001b[0m","\u001b[0;31mAttributeError\u001b[0m                            Traceback (most recent call last)","\u001b[0;31mAttributeError\u001b[0m: 'MessageFactory' object has no attribute 'GetPrototype'"],"ename":"AttributeError","evalue":"'MessageFactory' object has no attribute 'GetPrototype'","output_type":"error"}],"execution_count":17},{"cell_type":"markdown","source":"Here's an example of how the tokenizer splits a text into \"tokens\" (which are like words, but can be sub-word pieces, as you see below):","metadata":{}},{"cell_type":"code","source":"tokz.tokenize(\"Hello World! This is your pilot speaking.\")","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:11:54.987190Z","iopub.execute_input":"2025-11-13T14:11:54.987713Z","iopub.status.idle":"2025-11-13T14:11:54.993702Z","shell.execute_reply.started":"2025-11-13T14:11:54.987684Z","shell.execute_reply":"2025-11-13T14:11:54.992884Z"}},"outputs":[{"execution_count":18,"output_type":"execute_result","data":{"text/plain":"['hello', 'world', '!', 'this', 'is', 'your', 'pilot', 'speaking', '.']"},"metadata":{}}],"execution_count":18},{"cell_type":"markdown","source":"Here's a simple function which tokenizes our inputs:","metadata":{}},{"cell_type":"code","source":"def tok_func(x): \n    return tokz(\n        x[\"input\"],\n        truncation=True,\n        padding=\"max_length\",\n        max_length=128,\n        return_tensors='pt'\n    )","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:11:54.994474Z","iopub.execute_input":"2025-11-13T14:11:54.994677Z","iopub.status.idle":"2025-11-13T14:11:55.007179Z","shell.execute_reply.started":"2025-11-13T14:11:54.994660Z","shell.execute_reply":"2025-11-13T14:11:55.006586Z"}},"outputs":[],"execution_count":19},{"cell_type":"markdown","source":"To run this quickly in parallel on every row in our dataset, use `map`:","metadata":{}},{"cell_type":"code","source":"tok_ds = ds.map(tok_func, batched=True)","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:11:55.008781Z","iopub.execute_input":"2025-11-13T14:11:55.009263Z","iopub.status.idle":"2025-11-13T14:12:17.860949Z","shell.execute_reply.started":"2025-11-13T14:11:55.009245Z","shell.execute_reply":"2025-11-13T14:12:17.860309Z"}},"outputs":[{"output_type":"display_data","data":{"text/plain":"Map:   0%|          | 0/11802 [00:00<?, ? examples/s]","application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"f39cb2cfba90403aad1c0d11388faddb"}},"metadata":{}}],"execution_count":20},{"cell_type":"markdown","source":"This adds a new item to our dataset called `input_ids`. For instance, here is the input and IDs for the first row of our data:","metadata":{}},{"cell_type":"code","source":"row = tok_ds[0]\nrow['input'], row['input_ids']","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:12:17.861834Z","iopub.execute_input":"2025-11-13T14:12:17.862147Z","iopub.status.idle":"2025-11-13T14:12:17.868438Z","shell.execute_reply.started":"2025-11-13T14:12:17.862121Z","shell.execute_reply":"2025-11-13T14:12:17.867711Z"}},"outputs":[{"execution_count":21,"output_type":"execute_result","data":{"text/plain":"('TITLE: A Phase II Trial of Aminopterin in Adults and Children With Refractory Acute Leukemia Grant Application Title: A Phase II Trial of Aminopterin in Acute Leukemia; SUMMARY: RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of aminopterin in treating patients who have refractory leukemia.; PHASE: Phase 2',\n [101,\n  2516,\n  1024,\n  1037,\n  4403,\n  2462,\n  3979,\n  1997,\n  13096,\n  13876,\n  23282,\n  1999,\n  6001,\n  1998,\n  2336,\n  2007,\n  25416,\n  22648,\n  7062,\n  11325,\n  25468,\n  3946,\n  4646,\n  2516,\n  1024,\n  1037,\n  4403,\n  2462,\n  3979,\n  1997,\n  13096,\n  13876,\n  23282,\n  1999,\n  11325,\n  25468,\n  1025,\n  12654,\n  1024,\n  11581,\n  2063,\n  1024,\n  5850,\n  2109,\n  1999,\n  27144,\n  2224,\n  2367,\n  3971,\n  2000,\n  2644,\n  4456,\n  4442,\n  2013,\n  16023,\n  2061,\n  2027,\n  2644,\n  3652,\n  2030,\n  3280,\n  1012,\n  3800,\n  1024,\n  4403,\n  2462,\n  3979,\n  2000,\n  2817,\n  1996,\n  12353,\n  1997,\n  13096,\n  13876,\n  23282,\n  1999,\n  12318,\n  5022,\n  2040,\n  2031,\n  25416,\n  22648,\n  7062,\n  25468,\n  1012,\n  1025,\n  4403,\n  1024,\n  4403,\n  1016,\n  102,\n  0,\n  0,\n  0,\n  0,\n  0,\n  0,\n  0,\n  0,\n  0,\n  0,\n  0,\n  0,\n  0,\n  0,\n  0,\n  0,\n  0,\n  0,\n  0,\n  0,\n  0,\n  0,\n  0,\n  0,\n  0,\n  0,\n  0,\n  0,\n  0,\n  0,\n  0,\n  0,\n  0,\n  0,\n  0,\n  0,\n  0])"},"metadata":{}}],"execution_count":21},{"cell_type":"markdown","source":"So, what are those IDs and where do they come from? The secret is that there's a list called vocab in the tokenizer which contains a unique integer for every possible token string. We can look them up like this, for instance to find the token for the word \"of\":","metadata":{}},{"cell_type":"code","source":"tokz.vocab['phase']","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:12:17.869243Z","iopub.execute_input":"2025-11-13T14:12:17.869787Z","iopub.status.idle":"2025-11-13T14:12:17.883102Z","shell.execute_reply.started":"2025-11-13T14:12:17.869762Z","shell.execute_reply":"2025-11-13T14:12:17.882459Z"}},"outputs":[{"execution_count":22,"output_type":"execute_result","data":{"text/plain":"4403"},"metadata":{}}],"execution_count":22},{"cell_type":"markdown","source":"Looking above at our input IDs, we do indeed see that 265 appears as expected.\n\nFinally, we need to prepare our labels. Transformers always assumes that your labels has the column name `labels`, but in our dataset it's currently `Success`. Therefore, we need to rename it:","metadata":{}},{"cell_type":"code","source":"tok_ds = tok_ds.rename_columns({'Success':'label'})","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:12:17.883774Z","iopub.execute_input":"2025-11-13T14:12:17.883956Z","iopub.status.idle":"2025-11-13T14:12:17.897742Z","shell.execute_reply.started":"2025-11-13T14:12:17.883941Z","shell.execute_reply":"2025-11-13T14:12:17.897158Z"}},"outputs":[],"execution_count":23},{"cell_type":"markdown","source":"Now that we've prepared our tokens and labels, we need to create our validation set.","metadata":{}},{"cell_type":"markdown","source":"## Preparing the Test and Validation Sets","metadata":{}},{"cell_type":"markdown","source":"How do we recognise whether our models are under-fit, over-fit, or \"just right\"? We use a validation set. This is a set of data that we \"hold out\" from training -- we don't let our model see it at all. The validation set is only ever used to see how we're doing. It's never used as inputs to training the model. \n\nMetrics (measurements of the accuracy of a model) are calculated using the validation set, to compare different models during model evaluation (by trying different models, training methods, data processing) and select the best one. But be careful! Over time, model selection can over-fit to the validation set! This means that, when comparing many different models, there is some chance that a model will perform particularly well on the validation set by chance. This is the reason that, at the end of model selection and training, the model must be evaluated again on the test set that is held out and unseen during this entire process.\n\nWe'll use `eval` as our name for the test set, to avoid confusion with the `test` dataset that is created using the `transformers` library to be the validation set.\n\n`transformers` uses a `DatasetDict` for holding your training and validation sets. To create one that contains 25% of our data for the validation set, and 75% for the training set, you can use `train_test_split`. BUT! A random sampling may not be the best method for splitting the dataset in some real-world cases; [this article (How (and why) to create a good validation set)](https://www.fast.ai/2017/11/13/validation-sets/) explains why. For time series, in particular, it is best to use different periods within the data for the validation and test sets, in order to measure the model's ability to predict future events, not just interpolate missing points from within the time series.\n\nFor now, we'll use a random split.\n\n### Stratified Splitting\n\nRecall from earlier that we noticed a class imbalance in the target `label` class, with far more 1s (successful trials) than 0s (unsuccessful trials). We need to account for this at this point when splitting the dataset, making sure that each split (train, validation, test) has roughly the same proportion of each class (0 and 1) as the full dataset — otherwise, the model might overfit or fail to generalize. To do this, we will use *stratified sampling*, which preserves the class distribution across splits.","metadata":{}},{"cell_type":"code","source":"tok_ds = tok_ds.class_encode_column(\"label\")","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:12:17.898451Z","iopub.execute_input":"2025-11-13T14:12:17.898646Z","iopub.status.idle":"2025-11-13T14:12:18.059574Z","shell.execute_reply.started":"2025-11-13T14:12:17.898631Z","shell.execute_reply":"2025-11-13T14:12:18.058715Z"}},"outputs":[{"output_type":"display_data","data":{"text/plain":"Stringifying the column:   0%|          | 0/11802 [00:00<?, ? examples/s]","application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"6572370031fb4688895521fcf5c96749"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":"Casting to class labels:   0%|          | 0/11802 [00:00<?, ? examples/s]","application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"5b6fd42b4bce4649bf763e7b6638850e"}},"metadata":{}}],"execution_count":24},{"cell_type":"code","source":"from datasets import load_dataset\n\n# Split entire data set into training and testing data sets (80%/20%)\n# Use stratification to ensure roughly equal proportion of each target class in each\ntrain_test = tok_ds.train_test_split(\n    test_size=0.2,\n    stratify_by_column=\"label\",\n    seed=42\n)\n# Split training data into train/val (60%/20%)\nval_train = train_test[\"train\"].train_test_split(\n    test_size=0.2,\n    stratify_by_column=\"label\",\n    seed=42\n)\n\n# Combine into a DatasetDict\ndds = DatasetDict({\n    \"train\": val_train[\"train\"],\n    \"validation\": val_train[\"test\"],\n    \"test\": train_test[\"test\"]\n})","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:12:18.060703Z","iopub.execute_input":"2025-11-13T14:12:18.060966Z","iopub.status.idle":"2025-11-13T14:12:20.317008Z","shell.execute_reply.started":"2025-11-13T14:12:18.060939Z","shell.execute_reply":"2025-11-13T14:12:20.316410Z"}},"outputs":[],"execution_count":25},{"cell_type":"code","source":"dds","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:12:20.319233Z","iopub.execute_input":"2025-11-13T14:12:20.319713Z","iopub.status.idle":"2025-11-13T14:12:20.324595Z","shell.execute_reply.started":"2025-11-13T14:12:20.319694Z","shell.execute_reply":"2025-11-13T14:12:20.324010Z"}},"outputs":[{"execution_count":26,"output_type":"execute_result","data":{"text/plain":"DatasetDict({\n    train: Dataset({\n        features: ['index', 'NCT', 'Sponsor', 'Title', 'Summary', 'Start_Year', 'Start_Month', 'Phase', 'Enrollment', 'Status', 'Condition', 'label', 'input', '__index_level_0__', 'input_ids', 'attention_mask'],\n        num_rows: 7552\n    })\n    validation: Dataset({\n        features: ['index', 'NCT', 'Sponsor', 'Title', 'Summary', 'Start_Year', 'Start_Month', 'Phase', 'Enrollment', 'Status', 'Condition', 'label', 'input', '__index_level_0__', 'input_ids', 'attention_mask'],\n        num_rows: 1889\n    })\n    test: Dataset({\n        features: ['index', 'NCT', 'Sponsor', 'Title', 'Summary', 'Start_Year', 'Start_Month', 'Phase', 'Enrollment', 'Status', 'Condition', 'label', 'input', '__index_level_0__', 'input_ids', 'attention_mask'],\n        num_rows: 2361\n    })\n})"},"metadata":{}}],"execution_count":26},{"cell_type":"markdown","source":"# Model Training\n\n","metadata":{}},{"cell_type":"markdown","source":"## Defining the Metrics\n\nMetrics are used to evaluate the model's performance on the validation (and test) set, and compare models to each other to select the best one. It is important to select the right metrics for the problem at hand: in this case, an imbalanced binary classification problem.\n\nWe will use:\n- F1-macro score: balances precision (how many predicted positives were correct) and recall (how many actual positives were found).\n- ROC–AUC (Area Under the ROC Curve): Measures ranking quality (how well the model separates 0s and 1s), insensitive to class imbalance BUT can be over-optimistic when the imbalance is extreme (in that case, Precision–Recall AUC (PR-AUC) is better).","metadata":{}},{"cell_type":"code","source":"from sklearn.metrics import f1_score, precision_recall_fscore_support, roc_auc_score, average_precision_score\nimport numpy as np\n# from datasets import load_metric","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:12:20.325186Z","iopub.execute_input":"2025-11-13T14:12:20.325420Z","iopub.status.idle":"2025-11-13T14:12:20.340147Z","shell.execute_reply.started":"2025-11-13T14:12:20.325403Z","shell.execute_reply":"2025-11-13T14:12:20.339429Z"}},"outputs":[],"execution_count":27},{"cell_type":"code","source":"def corr(x,y): return np.corrcoef(x,y)[0][1]\ndef corr_d(eval_pred): return {'pearson': corr(*eval_pred)}","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:12:20.340839Z","iopub.execute_input":"2025-11-13T14:12:20.341040Z","iopub.status.idle":"2025-11-13T14:12:20.356512Z","shell.execute_reply.started":"2025-11-13T14:12:20.341008Z","shell.execute_reply":"2025-11-13T14:12:20.355862Z"}},"outputs":[],"execution_count":28},{"cell_type":"code","source":"# def compute_metrics(eval_pred):\n#     logits, labels = eval_pred\n#     preds = np.argmax(logits, axis=-1)\n#     probs = np.exp(logits) / np.exp(logits).sum(-1, keepdims=True)  # softmax for probabilities\n\n#     precision, recall, f1_macro, _ = precision_recall_fscore_support(\n#         labels, preds, average='macro'\n#     )\n\n#     roc_auc = roc_auc_score(labels, probs[:, 1])\n#     pr_auc = average_precision_score(labels, probs[:, 1])\n\n#     return {\n#         'precision_macro': precision,\n#         'recall_macro': recall,\n#         'f1_macro': f1_macro,\n#         'roc_auc': roc_auc,\n#         'pr_auc': pr_auc\n#     }\n\ndef compute_metrics(eval_pred):\n    logits, labels = eval_pred\n\n    # Convert logits to predicted class IDs\n    preds = np.argmax(logits, axis=-1)\n\n    # Precision, recall, F1 (macro)\n    precision, recall, f1_macro, _ = precision_recall_fscore_support(\n        labels, preds, average='macro'\n    )\n\n    # ROC-AUC requires probabilities for the positive class\n    probs = np.exp(logits) / np.exp(logits).sum(-1, keepdims=True)  # softmax\n    roc_auc = roc_auc_score(labels, probs[:, 1])\n\n    return {\n        'precision_macro': precision,\n        'recall_macro': recall,\n        'f1_macro': f1_macro,\n        'roc_auc': roc_auc\n    }","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:12:20.357215Z","iopub.execute_input":"2025-11-13T14:12:20.357456Z","iopub.status.idle":"2025-11-13T14:12:20.371249Z","shell.execute_reply.started":"2025-11-13T14:12:20.357439Z","shell.execute_reply":"2025-11-13T14:12:20.370509Z"}},"outputs":[],"execution_count":29},{"cell_type":"code","source":"data_collator = DataCollatorWithPadding(tokz)","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:12:20.372282Z","iopub.execute_input":"2025-11-13T14:12:20.372607Z","iopub.status.idle":"2025-11-13T14:12:20.390673Z","shell.execute_reply.started":"2025-11-13T14:12:20.372583Z","shell.execute_reply":"2025-11-13T14:12:20.389928Z"}},"outputs":[],"execution_count":30},{"cell_type":"code","source":"# Remove all cols except inputs and labels. Reformat lists as Tensors\ndef reformat_dds(df):\n    d = df.remove_columns([c for c in df.column_names if c not in [\"input_ids\", \"attention_mask\", \"label\"]])\n    d.set_format(type=\"torch\", columns=[\"input_ids\", \"attention_mask\", \"label\"])\n    return d\n\ndds[\"train\"] = reformat_dds(dds[\"train\"])\ndds[\"validation\"] = reformat_dds(dds[\"validation\"])\ndds[\"test\"] = reformat_dds(dds[\"test\"])","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:12:20.391343Z","iopub.execute_input":"2025-11-13T14:12:20.391547Z","iopub.status.idle":"2025-11-13T14:12:20.409637Z","shell.execute_reply.started":"2025-11-13T14:12:20.391532Z","shell.execute_reply":"2025-11-13T14:12:20.409025Z"}},"outputs":[],"execution_count":31},{"cell_type":"code","source":"# Check everything is formatted correctly\ndef check_format(df):\n    if set(df.column_names) != {'label', 'input_ids', 'attention_mask'}:\n        return False\n    correct_format = {'input_ids': torch.Tensor, 'attention_mask': torch.Tensor, 'label': torch.Tensor}\n    for i in range(3):\n        row = df[i]\n        for k in correct_format:\n            if not isinstance(row[k], torch.Tensor):\n                return False\n    return True\n\n\nprint(f\"Training set passed checks: {check_format(dds['train'])}\")\nprint(f\"Validation set passed checks: {check_format(dds['validation'])}\")\nprint(f\"Test set passed checks: {check_format(dds['test'])}\")","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:12:20.410393Z","iopub.execute_input":"2025-11-13T14:12:20.410622Z","iopub.status.idle":"2025-11-13T14:12:20.426925Z","shell.execute_reply.started":"2025-11-13T14:12:20.410597Z","shell.execute_reply":"2025-11-13T14:12:20.426196Z"}},"outputs":[{"name":"stdout","text":"Training set passed checks: True\nValidation set passed checks: True\nTest set passed checks: True\n","output_type":"stream"}],"execution_count":32},{"cell_type":"markdown","source":"## Training the Model","metadata":{}},{"cell_type":"code","source":"from transformers import TrainingArguments,Trainer,EarlyStoppingCallback","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:12:20.427691Z","iopub.execute_input":"2025-11-13T14:12:20.427896Z","iopub.status.idle":"2025-11-13T14:12:20.739419Z","shell.execute_reply.started":"2025-11-13T14:12:20.427880Z","shell.execute_reply":"2025-11-13T14:12:20.738799Z"}},"outputs":[],"execution_count":33},{"cell_type":"markdown","source":"In terms of the hyperparameters, we need to pick a batch size that fits our GPU, and a small number of epochs so we can run experiments quickly:","metadata":{}},{"cell_type":"code","source":"bs = 16\nepochs = 6","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:12:20.740077Z","iopub.execute_input":"2025-11-13T14:12:20.740282Z","iopub.status.idle":"2025-11-13T14:12:20.744028Z","shell.execute_reply.started":"2025-11-13T14:12:20.740264Z","shell.execute_reply":"2025-11-13T14:12:20.743217Z"}},"outputs":[],"execution_count":34},{"cell_type":"markdown","source":"The most important hyperparameter is the learning rate. fastai provides a learning rate finder to help you figure this out, but Transformers doesn't, so we'll just have to use trial and error. The idea is to find the largest value you can that doesn't cause oscillation and a worsening of the model's accuracy over time, but large enough that model training isn't too slow.","metadata":{}},{"cell_type":"code","source":"lr = 1e-5","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:12:20.744765Z","iopub.execute_input":"2025-11-13T14:12:20.744958Z","iopub.status.idle":"2025-11-13T14:12:20.758144Z","shell.execute_reply.started":"2025-11-13T14:12:20.744943Z","shell.execute_reply":"2025-11-13T14:12:20.757523Z"}},"outputs":[],"execution_count":35},{"cell_type":"markdown","source":"Transformers uses the `TrainingArguments` class to set up arguments. Don't worry too much about the values we're using here -- they should generally work fine in most cases. It's just the 3 parameters above that you may need to change for different models.","metadata":{}},{"cell_type":"code","source":"args = TrainingArguments(\n    # 'outputs', \n    output_dir = \"/kaggle/temp/results\", \n    learning_rate=lr, \n    warmup_ratio=0.1, \n    lr_scheduler_type='cosine', \n    fp16=True,\n    load_best_model_at_end=True,\n    metric_for_best_model=\"f1_macro\",  # choose best checkpoint by F1-macro\n    greater_is_better=True,\n    eval_strategy=\"epoch\",\n    save_strategy=\"epoch\",\n    per_device_train_batch_size=bs, \n    per_device_eval_batch_size=bs*2,\n    eval_accumulation_steps=1,   # avoids keeping all eval tensors in memory\n    gradient_accumulation_steps=2,\n    num_train_epochs=epochs, \n    weight_decay=0.01, \n    report_to='none'\n)","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:12:20.758794Z","iopub.execute_input":"2025-11-13T14:12:20.758956Z","iopub.status.idle":"2025-11-13T14:12:20.797197Z","shell.execute_reply.started":"2025-11-13T14:12:20.758943Z","shell.execute_reply":"2025-11-13T14:12:20.796441Z"}},"outputs":[],"execution_count":36},{"cell_type":"markdown","source":"We can now create our model, and `Trainer`, which is a class which combines the data and model together (just like `Learner` in fastai):","metadata":{}},{"cell_type":"code","source":"# model = AutoModelForSequenceClassification.from_pretrained(model_nm, num_labels=2)\n# model = DistilBertForSequenceClassification.from_pretrained(model_nm, num_labels=2, output_attentions=True)\nmodel = DistilBertForSequenceClassification.from_pretrained(model_nm, num_labels=2)\nmodel.to(\"cuda\")\n\ntrainer = Trainer(\n    model, \n    args, \n    train_dataset=dds['train'], \n    eval_dataset=dds['validation'],\n    tokenizer=tokz, \n    # compute_metrics=corr_d\n    data_collator=data_collator,\n    compute_metrics=compute_metrics\n    #callbacks=[EarlyStoppingCallback(early_stopping_patience=2)]\n)","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:17:36.560923Z","iopub.execute_input":"2025-11-13T14:17:36.561328Z","iopub.status.idle":"2025-11-13T14:17:36.984534Z","shell.execute_reply.started":"2025-11-13T14:17:36.561298Z","shell.execute_reply":"2025-11-13T14:17:36.983787Z"}},"outputs":[{"name":"stderr","text":"Some weights of DistilBertForSequenceClassification were not initialized from the model checkpoint at distilbert-base-uncased and are newly initialized: ['classifier.bias', 'classifier.weight', 'pre_classifier.bias', 'pre_classifier.weight']\nYou should probably TRAIN this model on a down-stream task to be able to use it for predictions and inference.\n/tmp/ipykernel_950/896617237.py:6: FutureWarning: `tokenizer` is deprecated and will be removed in version 5.0.0 for `Trainer.__init__`. Use `processing_class` instead.\n  trainer = Trainer(\n","output_type":"stream"}],"execution_count":41},{"cell_type":"markdown","source":"Now that we have the `model` and the `Trainer`, it's time to train our model!","metadata":{}},{"cell_type":"code","source":"import datasets\ndds = dds.cast_column(\"label\", datasets.Value(\"int64\"))\nprint(dds[\"train\"].features)","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:12:21.239987Z","iopub.execute_input":"2025-11-13T14:12:21.240471Z","iopub.status.idle":"2025-11-13T14:12:21.366955Z","shell.execute_reply.started":"2025-11-13T14:12:21.240451Z","shell.execute_reply":"2025-11-13T14:12:21.366113Z"}},"outputs":[{"output_type":"display_data","data":{"text/plain":"Casting the dataset:   0%|          | 0/7552 [00:00<?, ? examples/s]","application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"2efc0dbe4ea3476d9049b9ac1650b69a"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":"Casting the dataset:   0%|          | 0/1889 [00:00<?, ? examples/s]","application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"1891fd66020b400f97798a7529456129"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":"Casting the dataset:   0%|          | 0/2361 [00:00<?, ? examples/s]","application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"3f1c92fea49a4acf9bbafd51cc323931"}},"metadata":{}},{"name":"stdout","text":"{'label': Value('int64'), 'input_ids': List(Value('int32')), 'attention_mask': List(Value('int8'))}\n","output_type":"stream"}],"execution_count":38},{"cell_type":"code","source":"trainer.train()","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:17:43.137553Z","iopub.execute_input":"2025-11-13T14:17:43.138198Z","iopub.status.idle":"2025-11-13T14:22:51.555521Z","shell.execute_reply.started":"2025-11-13T14:17:43.138172Z","shell.execute_reply":"2025-11-13T14:22:51.554855Z"}},"outputs":[{"output_type":"display_data","data":{"text/plain":"<IPython.core.display.HTML object>","text/html":"\n    <div>\n      \n      <progress value='1416' max='1416' style='width:300px; height:20px; vertical-align: middle;'></progress>\n      [1416/1416 05:07, Epoch 6/6]\n    </div>\n    <table border=\"1\" class=\"dataframe\">\n  <thead>\n <tr style=\"text-align: left;\">\n      <th>Epoch</th>\n      <th>Training Loss</th>\n      <th>Validation Loss</th>\n      <th>Precision Macro</th>\n      <th>Recall Macro</th>\n      <th>F1 Macro</th>\n      <th>Roc Auc</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <td>1</td>\n      <td>No log</td>\n      <td>0.381116</td>\n      <td>0.434621</td>\n      <td>0.500000</td>\n      <td>0.465024</td>\n      <td>0.654696</td>\n    </tr>\n    <tr>\n      <td>2</td>\n      <td>No log</td>\n      <td>0.367058</td>\n      <td>0.434621</td>\n      <td>0.500000</td>\n      <td>0.465024</td>\n      <td>0.686513</td>\n    </tr>\n    <tr>\n      <td>3</td>\n      <td>0.404400</td>\n      <td>0.379132</td>\n      <td>0.434621</td>\n      <td>0.500000</td>\n      <td>0.465024</td>\n      <td>0.696777</td>\n    </tr>\n    <tr>\n      <td>4</td>\n      <td>0.404400</td>\n      <td>0.384929</td>\n      <td>0.659956</td>\n      <td>0.542583</td>\n      <td>0.548389</td>\n      <td>0.692326</td>\n    </tr>\n    <tr>\n      <td>5</td>\n      <td>0.314700</td>\n      <td>0.395258</td>\n      <td>0.661054</td>\n      <td>0.571712</td>\n      <td>0.588536</td>\n      <td>0.689655</td>\n    </tr>\n    <tr>\n      <td>6</td>\n      <td>0.314700</td>\n      <td>0.399974</td>\n      <td>0.663403</td>\n      <td>0.584861</td>\n      <td>0.603683</td>\n      <td>0.686326</td>\n    </tr>\n  </tbody>\n</table><p>"},"metadata":{}},{"name":"stderr","text":"/usr/local/lib/python3.11/dist-packages/sklearn/metrics/_classification.py:1344: UndefinedMetricWarning: Precision and F-score are ill-defined and being set to 0.0 in labels with no predicted samples. Use `zero_division` parameter to control this behavior.\n  _warn_prf(average, modifier, msg_start, len(result))\n/usr/local/lib/python3.11/dist-packages/sklearn/metrics/_classification.py:1344: UndefinedMetricWarning: Precision and F-score are ill-defined and being set to 0.0 in labels with no predicted samples. Use `zero_division` parameter to control this behavior.\n  _warn_prf(average, modifier, msg_start, len(result))\n/usr/local/lib/python3.11/dist-packages/sklearn/metrics/_classification.py:1344: UndefinedMetricWarning: Precision and F-score are ill-defined and being set to 0.0 in labels with no predicted samples. Use `zero_division` parameter to control this behavior.\n  _warn_prf(average, modifier, msg_start, len(result))\n","output_type":"stream"},{"execution_count":42,"output_type":"execute_result","data":{"text/plain":"TrainOutput(global_step=1416, training_loss=0.33200575402901, metrics={'train_runtime': 307.9972, 'train_samples_per_second': 147.118, 'train_steps_per_second': 4.597, 'total_flos': 1500590691975168.0, 'train_loss': 0.33200575402901, 'epoch': 6.0})"},"metadata":{}}],"execution_count":42},{"cell_type":"markdown","source":"# Model Evaluation\n\nLet's now use the trained model to predict the labels for the test set, and then compare these to the true labels to evaluate the model's performance:","metadata":{}},{"cell_type":"code","source":"results = trainer.evaluate(dds[\"test\"])\nprint(results)","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:23:03.513468Z","iopub.execute_input":"2025-11-13T14:23:03.514127Z","iopub.status.idle":"2025-11-13T14:23:07.997988Z","shell.execute_reply.started":"2025-11-13T14:23:03.514088Z","shell.execute_reply":"2025-11-13T14:23:07.997400Z"}},"outputs":[{"output_type":"display_data","data":{"text/plain":"<IPython.core.display.HTML object>","text/html":"\n    <div>\n      \n      <progress value='74' max='74' style='width:300px; height:20px; vertical-align: middle;'></progress>\n      [74/74 00:04]\n    </div>\n    "},"metadata":{}},{"name":"stdout","text":"{'eval_loss': 0.3946785628795624, 'eval_precision_macro': 0.603800306064918, 'eval_recall_macro': 0.5609753212589186, 'eval_f1_macro': 0.5713391625750284, 'eval_roc_auc': 0.7109174410315613, 'eval_runtime': 4.4758, 'eval_samples_per_second': 527.509, 'eval_steps_per_second': 16.534, 'epoch': 6.0}\n","output_type":"stream"}],"execution_count":43},{"cell_type":"markdown","source":"## Interpreting the Model Performance\n\n| Metric | Value | Interpretation |\n|---|---|---|\n|Eval Loss | 0.3947|Reasonable for binary classification. Lower is better; relative to cross-entropy, ~0.4 is acceptable.|\n|Precision Macro|0.604|On average, ~60% of predicted positives/negatives are correct. Shows good correctness across both classes.|\n|Recall Macro|0.561|Model captures ~56% of all true instances on average. Could be higher, but not bad for imbalanced data.|\n|F1 Macro|0.571|Balanced measure of precision & recall. Improvement over early runs (was ~0.465).|\n|ROC-AUC|0.711|Over 0.7 → the model ranks positive instances above negative ones well.|\n|Eval speed|~527 samples/sec\tFast, suitable for practical deployment.|","metadata":{}},{"cell_type":"markdown","source":"# Model Interpretability","metadata":{}},{"cell_type":"markdown","source":"## Gradient-based attribution (saliency maps)\n\nTechniques like Integrated Gradients, Saliency Maps, or Gradient SHAP from the Captum library can tell you which tokens contributed most to the predicted class.\n\nBelow, we use Integrated Gradients. The attribution of each word in the input text to the model's prediction is shown by the colour and depth of the word's highlighting. Deeper colours mean a stronger attribution. Red means that the word made a positive contribution (i.e. pushed the prediction closer to the target class 1; successful) while blue means that the word made a negative contribution (pushed the prediction away from the target class). ","metadata":{}},{"cell_type":"code","source":"# ! pip install captum\nfrom captum.attr import IntegratedGradients\nfrom matplotlib import cm\nfrom IPython.display import HTML, display\n\nexample_inputs = [\n    \"TITLE: Effects of Two Doses of a Common Cold Treatment on Cognitive Function; SUMMARY: This study will investigate any improvement in alertness and performance based on cognitive function and mood assessment in subjects suffering the common cold, when taking a novel paracetamol and caffeine combination verses paracetamol alone.; PHASE: Phase 3\", \n    \"TITLE: A Single Dose Study to Assess the Pharmacokinetics of SCH 900800 Administered as Oral Tablets in L-DOPA-treated Subjects With Parkinson's Disease; SUMMARY: This study is being done to assess the pharmacokinetics of SCH 900800 in participants with moderate to severe Parkinson's Disease (PD) being treated with L-DOPA.; PHASE: Phase 1\",\n    \"TITLE: A Registration Study of the Safety, Tolerability, and Immunogenicity of V441 in Healthy Infants in Taiwan; SUMMARY: The purpose of this study is to evaluate the safety, tolerability, and immune response of an investigational vaccine being evaluated to reduce the incidence of diphtheria, pertussis, tetanus, hepatitis B, poliomyelitis, and Haemophilus influenza type b.; PHASE: Phase 3\",\n    \"TITLE: A Phase IIIB, Multi-Center, Open Label Study For Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) in Combination With Exemestane: 4EVER - Efficacy, Safety, Health Economics, Translational Research; SUMMARY: The present multi-center, open-label, single-arm study aims to evaluate the efficacy and safety, quality of life and health resources utilization in postmenopausal women with hormone receptor positive breast cancer progressing following prior therapy with non-steroidal aromatase inhibitors (NSAI) treated with the combination of Everolimus and Exemestane.; PHASE: Phase 3\",\n    \"TITLE: A Multicenter, Randomized, Double-Blind, 'Crossover' Design Study to Evaluate the Lipid-Altering Efficacy and Safety of MK-0524B Combination Tablet Compared to MK-0524A + Simvastatin Coadministration in Patients With Primary Hypercholesterolemia and Mixed Dyslipidemia; SUMMARY: This is a 20-week clinical trial in participants with primary hypercholesterolemia or mixed dyslipidemia to demonstrate the effect of MK-0524B compared to MK-0524A + Simvastatin on lipid values.; PHASE: Phase 3\",\n    \"TITLE: A Multicenter, Randomized, Double-blind, Phase III Trial to Evaluate the Safety, Immunogenicity, and Efficacy of MSB11022 Compared With Humira¬Æ in Patients With Moderately to Severely Active Rheumatoid Arthritis; SUMMARY: The purpose of this study is to compare the efficacy, safety and immunogenicity of MSB11022 and Humira¬Æ in adult subjects with rheumatoid arthritis.; PHASE: Phase 3\",\n    \"TITLE: A Multicenter, Open-label Extension, Multiple Dose, Parallel Group Study To Investigate The Long-term Safety And Tolerability Of Aab-003 (Pf-05236812) Administered Intravenously In Subjects With Mild To Moderate Alzheimer's Disease Previously Treated With Aab-003 Or Placebo In Protocol B2601001; SUMMARY: This is a study to evaluate the safety and tolerability of multiple doses of AAB-003 (PF-05236812) in patients with mild to moderate Alzheimer's Disease. Patients who complete study B2601001 may participate in this trial and receive AAB-003 (PF-05236812). Each patient's participation will last approximately 52 weeks.; PHASE: Phase 1\",\n    \"TITLE: A Phase III Randomized, Double-blind, Controlled Study Comparing Clofarabine and Cytarabine Versus Cytarabine Alone in Adult Patients 55 Years and Older With Acute Myelogenous Leukemia (AML) Who Have Relapsed or Are Refractory After Receiving up to Two Prior Induction Regimens; SUMMARY: Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed acute or refractory lymphoblastic leukemia (ALL) who have had at least 2 prior treatment regimens. There is no recommended standard treatment for relapsed or refractory acute myelogenous leukemia in older patients. Cytarabine is the most commonly used drug to treat these patients. This study will determine if there is benefit by combining clofarabine with cytarabine. Patients will be randomized to receive up to 3 cycles of treatment with either placebo in combination with cytarabine or clofarabine in combination with cytarabine. Randomization was stratified by remission status following the first induction regimen (no remission [i.e., CR1 = refractory] or remission <6 months vs CR1 = remission ‚â•6 months). CR1 is defined as remission after first pre-study induction regimen. The safety and tolerability of clofarabine in combination with cytarabine and cytarabine alone will be monitored throughout the study.; PHASE: Phase 3\",\n    \"TITLE: A Phase 2 Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Ranging Study Of TBC3711 In Subjects With Resistant Hypertension; SUMMARY: The study was to determine the safe and effective dose of TBC3711 in patients with uncontrolled high blood pressure while already taking blood pressure medications.; PHASE: Phase 2\",\n    \"TITLE: A Multicenter, Open Label, Phase 1B Study of Escalating Doses of RO5045337 Administered Orally, With Cytarabine Administered A) Subcutaneously, or B) Intravenously, in Patients With Acute Myelogenous Leukemia (AML); SUMMARY: This multi-center, open-label, Phase 1b study will evaluate the safety, pharmacokinetics and efficacy of RO5045337 in combination with cytarabine in patients with acute myelogenous leukemia. In Arm A, cohorts of previously untreated patients deemed unsuitable for standard induction therapy will receive escalating oral doses of RO5045377 and cytarabine 20 mg/m2 subcutaneously daily for Days 1 to 10 of each 28-day cycle. In Arm B, cohorts of patients who have relapsed or are refractory after at least one cytarabine/anthracycline containing regimen will receive escalating oral doses of RO5045377 on Days 1 to 5 and cytarabine 1 gm/m2 intravenously on Days 1 to 6 of each 28-day cycle. Patients will receive up to 4 cycles of therapy, patients in Arm A who achieve hematologic response may continue additional cycles until disease progression.; PHASE: Phase 1\"\n]\n\ndef gradient_based_attribution(text):\n    device = torch.device(\"cuda\" if torch.cuda.is_available() else \"cpu\")\n    # Tokenize input\n    model.to(device)\n    inputs = tokz(text, return_tensors=\"pt\")\n    input_ids = inputs[\"input_ids\"].to(device)  \n    attention_mask = inputs[\"attention_mask\"].to(device)\n    \n    # Get embeddings for the tokens\n    embeddings = model.distilbert.embeddings(input_ids)  # FloatTensor [1, seq_len, hidden_size]\n    embeddings.requires_grad_()  # Important for gradients\n\n    # Define forward function taking embeddings as input\n    def forward_embeds(embeds, attention_mask):\n        outputs = model.distilbert(inputs_embeds=embeds, attention_mask=attention_mask)\n        cls_embeds = outputs.last_hidden_state[:, 0, :]\n        logits = model.classifier(cls_embeds)\n        return logits\n    \n    # Initialize IntegratedGradients\n    ig = IntegratedGradients(forward_embeds)\n    \n    # Compute attributions\n    attr, delta = ig.attribute(\n        embeddings,  # Float tensor, requires_grad=True\n        additional_forward_args=(attention_mask,),\n        target=1,  # class index\n        return_convergence_delta=True\n    )\n\n    # Summarize token importance\n    token_importance = attr.sum(dim=-1).squeeze(0).detach().cpu().numpy()\n    tokens = tokz.convert_ids_to_tokens(input_ids.squeeze(0).cpu())\n    \n    # Normalize attributions for color mapping\n    max_val = np.max(np.abs(token_importance)) + 1e-10  # avoid div by zero\n    norm_attr = token_importance / max_val\n    \n    # # Sort tokens by absolute attribution\n    # sorted_indices = np.argsort(np.abs(token_importance))[::-1]  # descending by strength\n    # print(f\"{'Token':15} {'Attribution':>12}\")\n    # print(\"-\" * 28)\n    # for idx in sorted_indices:\n    #     print(f\"{tokens[idx]:15} {token_importance[idx]:12.4f}\")\n\n    # Generate HTML color-coded text\n    def colorize_token(token, score):\n        \"\"\"\n        Red = positive contribution, Blue = negative contribution\n        \"\"\"\n        cmap = cm.bwr  # blue-white-red colormap\n        color = cmap(0.5 + 0.5 * score)  # map [-1,1] to [0,1]\n        color_hex = \"#{:02x}{:02x}{:02x}\".format(\n            int(color[0]*255), int(color[1]*255), int(color[2]*255)\n        )\n        return f\"<span style='background-color:{color_hex}'>{token} </span>\"\n    \n    colored_tokens = [colorize_token(t, s) for t, s in zip(tokens, norm_attr)]\n    html_str = \" \".join(colored_tokens)\n    \n    display(HTML(html_str))\n\nfor i in range(0, len(example_inputs)):\n    gradient_based_attribution(example_inputs[i])\n    print(\"\\n\")","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:24:23.503419Z","iopub.execute_input":"2025-11-13T14:24:23.504128Z","iopub.status.idle":"2025-11-13T14:24:26.245008Z","shell.execute_reply.started":"2025-11-13T14:24:23.504099Z","shell.execute_reply":"2025-11-13T14:24:26.244390Z"}},"outputs":[{"output_type":"display_data","data":{"text/plain":"<IPython.core.display.HTML object>","text/html":"<span style='background-color:#ffb6b6'>[CLS] </span> <span style='background-color:#ff0000'>title </span> <span style='background-color:#ffe4e4'>: </span> <span style='background-color:#ffc6c6'>effects </span> <span style='background-color:#fffcfc'>of </span> <span style='background-color:#ffd2d2'>two </span> <span style='background-color:#f8f8ff'>doses </span> <span style='background-color:#ffc0c0'>of </span> <span style='background-color:#c3c3ff'>a </span> <span style='background-color:#fefeff'>common </span> <span style='background-color:#fafaff'>cold </span> <span style='background-color:#ceceff'>treatment </span> <span style='background-color:#e8e8ff'>on </span> <span style='background-color:#ffecec'>cognitive </span> <span style='background-color:#f0f0ff'>function </span> <span style='background-color:#ffc6c6'>; </span> <span style='background-color:#ffc6c6'>summary </span> <span style='background-color:#ffb8b8'>: </span> <span style='background-color:#ffe6e6'>this </span> <span style='background-color:#e6e6ff'>study </span> <span style='background-color:#fffefe'>will </span> <span style='background-color:#fff0f0'>investigate </span> <span style='background-color:#fffafa'>any </span> <span style='background-color:#fff0f0'>improvement </span> <span style='background-color:#fff2f2'>in </span> <span style='background-color:#f6f6ff'>alert </span> <span style='background-color:#e8e8ff'>##ness </span> <span style='background-color:#ffd8d8'>and </span> <span style='background-color:#ffecec'>performance </span> <span style='background-color:#f2f2ff'>based </span> <span style='background-color:#fffefe'>on </span> <span style='background-color:#ffe6e6'>cognitive </span> <span style='background-color:#eeeeff'>function </span> <span style='background-color:#ffecec'>and </span> <span style='background-color:#ffcccc'>mood </span> <span style='background-color:#ffd3d3'>assessment </span> <span style='background-color:#ccccff'>in </span> <span style='background-color:#f0f0ff'>subjects </span> <span style='background-color:#d2d2ff'>suffering </span> <span style='background-color:#ffb6b6'>the </span> <span style='background-color:#b8b8ff'>common </span> <span style='background-color:#d8d8ff'>cold </span> <span style='background-color:#ffdada'>, </span> <span style='background-color:#fff6f6'>when </span> <span style='background-color:#ececff'>taking </span> <span style='background-color:#fff8f8'>a </span> <span style='background-color:#e0e0ff'>novel </span> <span style='background-color:#fafaff'>para </span> <span style='background-color:#f3f3ff'>##ce </span> <span style='background-color:#dedeff'>##tam </span> <span style='background-color:#e8e8ff'>##ol </span> <span style='background-color:#ccccff'>and </span> <span style='background-color:#f3f3ff'>caf </span> <span style='background-color:#f0f0ff'>##fe </span> <span style='background-color:#e8e8ff'>##ine </span> <span style='background-color:#e3e3ff'>combination </span> <span style='background-color:#c6c6ff'>verses </span> <span style='background-color:#fff4f4'>para </span> <span style='background-color:#eeeeff'>##ce </span> <span style='background-color:#eeeeff'>##tam </span> <span style='background-color:#e8e8ff'>##ol </span> <span style='background-color:#cacaff'>alone </span> <span style='background-color:#e2e2ff'>. </span> <span style='background-color:#d8d8ff'>; </span> <span style='background-color:#ececff'>phase </span> <span style='background-color:#fcfcff'>: </span> <span style='background-color:#fff4f4'>phase </span> <span style='background-color:#ffd6d6'>3 </span> <span style='background-color:#ff5454'>[SEP] </span>"},"metadata":{}},{"name":"stdout","text":"\n\n","output_type":"stream"},{"output_type":"display_data","data":{"text/plain":"<IPython.core.display.HTML object>","text/html":"<span style='background-color:#ffdada'>[CLS] </span> <span style='background-color:#ffbebe'>title </span> <span style='background-color:#ffe8e8'>: </span> <span style='background-color:#ffeeee'>a </span> <span style='background-color:#e0e0ff'>single </span> <span style='background-color:#ffdede'>dose </span> <span style='background-color:#ffd6d6'>study </span> <span style='background-color:#fff0f0'>to </span> <span style='background-color:#ffeaea'>assess </span> <span style='background-color:#fffcfc'>the </span> <span style='background-color:#e3e3ff'>ph </span> <span style='background-color:#e8e8ff'>##arm </span> <span style='background-color:#fff2f2'>##aco </span> <span style='background-color:#fff8f8'>##kin </span> <span style='background-color:#eeeeff'>##etic </span> <span style='background-color:#ffdada'>##s </span> <span style='background-color:#eaeaff'>of </span> <span style='background-color:#ffeeee'>sc </span> <span style='background-color:#f8f8ff'>##h </span> <span style='background-color:#f3f3ff'>900 </span> <span style='background-color:#fffcfc'>##80 </span> <span style='background-color:#f8f8ff'>##0 </span> <span style='background-color:#fff4f4'>administered </span> <span style='background-color:#fff4f4'>as </span> <span style='background-color:#f2f2ff'>oral </span> <span style='background-color:#fafaff'>tablets </span> <span style='background-color:#f0f0ff'>in </span> <span style='background-color:#ffe6e6'>l </span> <span style='background-color:#fcfcff'>- </span> <span style='background-color:#ffe0e0'>do </span> <span style='background-color:#ffecec'>##pa </span> <span style='background-color:#ffeaea'>- </span> <span style='background-color:#c6c6ff'>treated </span> <span style='background-color:#f6f6ff'>subjects </span> <span style='background-color:#eeeeff'>with </span> <span style='background-color:#ffeaea'>parkinson </span> <span style='background-color:#dedeff'>' </span> <span style='background-color:#fefeff'>s </span> <span style='background-color:#d8d8ff'>disease </span> <span style='background-color:#fff0f0'>; </span> <span style='background-color:#ffe6e6'>summary </span> <span style='background-color:#fff0f0'>: </span> <span style='background-color:#ffecec'>this </span> <span style='background-color:#eaeaff'>study </span> <span style='background-color:#f8f8ff'>is </span> <span style='background-color:#fcfcff'>being </span> <span style='background-color:#f2f2ff'>done </span> <span style='background-color:#f2f2ff'>to </span> <span style='background-color:#fff6f6'>assess </span> <span style='background-color:#ffd3d3'>the </span> <span style='background-color:#fffefe'>ph </span> <span style='background-color:#eeeeff'>##arm </span> <span style='background-color:#fff8f8'>##aco </span> <span style='background-color:#ececff'>##kin </span> <span style='background-color:#e2e2ff'>##etic </span> <span style='background-color:#fff0f0'>##s </span> <span style='background-color:#e6e6ff'>of </span> <span style='background-color:#fff8f8'>sc </span> <span style='background-color:#f2f2ff'>##h </span> <span style='background-color:#e6e6ff'>900 </span> <span style='background-color:#fff6f6'>##80 </span> <span style='background-color:#fff8f8'>##0 </span> <span style='background-color:#e3e3ff'>in </span> <span style='background-color:#ffe8e8'>participants </span> <span style='background-color:#fff0f0'>with </span> <span style='background-color:#fffefe'>moderate </span> <span style='background-color:#ffdada'>to </span> <span style='background-color:#eeeeff'>severe </span> <span style='background-color:#f6f6ff'>parkinson </span> <span style='background-color:#d2d2ff'>' </span> <span style='background-color:#e3e3ff'>s </span> <span style='background-color:#ececff'>disease </span> <span style='background-color:#e6e6ff'>( </span> <span style='background-color:#fcfcff'>pd </span> <span style='background-color:#fffafa'>) </span> <span style='background-color:#fafaff'>being </span> <span style='background-color:#fff8f8'>treated </span> <span style='background-color:#fff8f8'>with </span> <span style='background-color:#ffe6e6'>l </span> <span style='background-color:#fff4f4'>- </span> <span style='background-color:#fffefe'>do </span> <span style='background-color:#fff8f8'>##pa </span> <span style='background-color:#fff2f2'>. </span> <span style='background-color:#f3f3ff'>; </span> <span style='background-color:#f3f3ff'>phase </span> <span style='background-color:#eaeaff'>: </span> <span style='background-color:#fcfcff'>phase </span> <span style='background-color:#f2f2ff'>1 </span> <span style='background-color:#ff0000'>[SEP] </span>"},"metadata":{}},{"name":"stdout","text":"\n\n","output_type":"stream"},{"output_type":"display_data","data":{"text/plain":"<IPython.core.display.HTML object>","text/html":"<span style='background-color:#ffbaba'>[CLS] </span> <span style='background-color:#ff0000'>title </span> <span style='background-color:#ff8282'>: </span> <span style='background-color:#ffe2e2'>a </span> <span style='background-color:#f0f0ff'>registration </span> <span style='background-color:#fffcfc'>study </span> <span style='background-color:#fff8f8'>of </span> <span style='background-color:#ffcaca'>the </span> <span style='background-color:#fff8f8'>safety </span> <span style='background-color:#ffeeee'>, </span> <span style='background-color:#ffe4e4'>to </span> <span style='background-color:#f0f0ff'>##ler </span> <span style='background-color:#fffefe'>##ability </span> <span style='background-color:#f8f8ff'>, </span> <span style='background-color:#fafaff'>and </span> <span style='background-color:#fafaff'>im </span> <span style='background-color:#fafaff'>##mun </span> <span style='background-color:#f6f6ff'>##ogenic </span> <span style='background-color:#fefeff'>##ity </span> <span style='background-color:#fff0f0'>of </span> <span style='background-color:#dcdcff'>v </span> <span style='background-color:#fffafa'>##44 </span> <span style='background-color:#ffe6e6'>##1 </span> <span style='background-color:#fcfcff'>in </span> <span style='background-color:#f2f2ff'>healthy </span> <span style='background-color:#f8f8ff'>infants </span> <span style='background-color:#f2f2ff'>in </span> <span style='background-color:#ffacac'>taiwan </span> <span style='background-color:#ffb2b2'>; </span> <span style='background-color:#fff0f0'>summary </span> <span style='background-color:#ffb6b6'>: </span> <span style='background-color:#ffc2c2'>the </span> <span style='background-color:#dadaff'>purpose </span> <span style='background-color:#fff6f6'>of </span> <span style='background-color:#fff6f6'>this </span> <span style='background-color:#f8f8ff'>study </span> <span style='background-color:#ffe4e4'>is </span> <span style='background-color:#e6e6ff'>to </span> <span style='background-color:#fffcfc'>evaluate </span> <span style='background-color:#ffdede'>the </span> <span style='background-color:#f0f0ff'>safety </span> <span style='background-color:#ffe2e2'>, </span> <span style='background-color:#e2e2ff'>to </span> <span style='background-color:#f8f8ff'>##ler </span> <span style='background-color:#f3f3ff'>##ability </span> <span style='background-color:#fffcfc'>, </span> <span style='background-color:#ffe2e2'>and </span> <span style='background-color:#d0d0ff'>immune </span> <span style='background-color:#f8f8ff'>response </span> <span style='background-color:#ececff'>of </span> <span style='background-color:#f6f6ff'>an </span> <span style='background-color:#e8e8ff'>investigation </span> <span style='background-color:#ffd6d6'>##al </span> <span style='background-color:#cacaff'>vaccine </span> <span style='background-color:#fffafa'>being </span> <span style='background-color:#fffafa'>evaluated </span> <span style='background-color:#d8d8ff'>to </span> <span style='background-color:#f2f2ff'>reduce </span> <span style='background-color:#fff6f6'>the </span> <span style='background-color:#e8e8ff'>incidence </span> <span style='background-color:#c8c8ff'>of </span> <span style='background-color:#fff4f4'>dip </span> <span style='background-color:#d8d8ff'>##ht </span> <span style='background-color:#c3c3ff'>##her </span> <span style='background-color:#fff0f0'>##ia </span> <span style='background-color:#7e7eff'>, </span> <span style='background-color:#fff8f8'>per </span> <span style='background-color:#ffdcdc'>##tus </span> <span style='background-color:#fffefe'>##sis </span> <span style='background-color:#d8d8ff'>, </span> <span style='background-color:#f2f2ff'>te </span> <span style='background-color:#fcfcff'>##tan </span> <span style='background-color:#fcfcff'>##us </span> <span style='background-color:#fffefe'>, </span> <span style='background-color:#fefeff'>hepatitis </span> <span style='background-color:#d8d8ff'>b </span> <span style='background-color:#f6f6ff'>, </span> <span style='background-color:#fffafa'>pol </span> <span style='background-color:#f0f0ff'>##iom </span> <span style='background-color:#fffcfc'>##ye </span> <span style='background-color:#dcdcff'>##lit </span> <span style='background-color:#f3f3ff'>##is </span> <span style='background-color:#dcdcff'>, </span> <span style='background-color:#f6f6ff'>and </span> <span style='background-color:#f0f0ff'>ha </span> <span style='background-color:#fffcfc'>##em </span> <span style='background-color:#fffafa'>##op </span> <span style='background-color:#e6e6ff'>##hil </span> <span style='background-color:#fffafa'>##us </span> <span style='background-color:#c6c6ff'>influenza </span> <span style='background-color:#ececff'>type </span> <span style='background-color:#fafaff'>b </span> <span style='background-color:#f2f2ff'>. </span> <span style='background-color:#eaeaff'>; </span> <span style='background-color:#fefeff'>phase </span> <span style='background-color:#dcdcff'>: </span> <span style='background-color:#ffe8e8'>phase </span> <span style='background-color:#fafaff'>3 </span> <span style='background-color:#ff2e2e'>[SEP] </span>"},"metadata":{}},{"name":"stdout","text":"\n\n","output_type":"stream"},{"output_type":"display_data","data":{"text/plain":"<IPython.core.display.HTML object>","text/html":"<span style='background-color:#9393ff'>[CLS] </span> <span style='background-color:#ff0000'>title </span> <span style='background-color:#ffa8a8'>: </span> <span style='background-color:#aaaaff'>a </span> <span style='background-color:#fff8f8'>phase </span> <span style='background-color:#ffaeae'>iii </span> <span style='background-color:#e8e8ff'>##b </span> <span style='background-color:#ff9292'>, </span> <span style='background-color:#ffe8e8'>multi </span> <span style='background-color:#ffecec'>- </span> <span style='background-color:#f8f8ff'>center </span> <span style='background-color:#f6f6ff'>, </span> <span style='background-color:#ffdcdc'>open </span> <span style='background-color:#fefeff'>label </span> <span style='background-color:#dedeff'>study </span> <span style='background-color:#e2e2ff'>for </span> <span style='background-color:#f8f8ff'>post </span> <span style='background-color:#ffdede'>##men </span> <span style='background-color:#ffd0d0'>##opa </span> <span style='background-color:#ffe6e6'>##usa </span> <span style='background-color:#ccccff'>##l </span> <span style='background-color:#f3f3ff'>women </span> <span style='background-color:#ffa8a8'>with </span> <span style='background-color:#d3d3ff'>est </span> <span style='background-color:#c6c6ff'>##rogen </span> <span style='background-color:#dcdcff'>receptor </span> <span style='background-color:#c2c2ff'>positive </span> <span style='background-color:#ffa0a0'>locally </span> <span style='background-color:#fafaff'>advanced </span> <span style='background-color:#fff8f8'>or </span> <span style='background-color:#fffcfc'>meta </span> <span style='background-color:#acacff'>##static </span> <span style='background-color:#ffd3d3'>breast </span> <span style='background-color:#eeeeff'>cancer </span> <span style='background-color:#aaaaff'>treated </span> <span style='background-color:#ffe0e0'>with </span> <span style='background-color:#ffdcdc'>ever </span> <span style='background-color:#ff7474'>##oli </span> <span style='background-color:#c6c6ff'>##mus </span> <span style='background-color:#eeeeff'>( </span> <span style='background-color:#fff2f2'>ra </span> <span style='background-color:#b8b8ff'>##d </span> <span style='background-color:#eeeeff'>##00 </span> <span style='background-color:#fefeff'>##1 </span> <span style='background-color:#d6d6ff'>) </span> <span style='background-color:#e8e8ff'>in </span> <span style='background-color:#f8f8ff'>combination </span> <span style='background-color:#ffe2e2'>with </span> <span style='background-color:#f0f0ff'>ex </span> <span style='background-color:#dadaff'>##eme </span> <span style='background-color:#dadaff'>##stan </span> <span style='background-color:#ffe2e2'>##e </span> <span style='background-color:#f8f8ff'>: </span> <span style='background-color:#fffcfc'>4 </span> <span style='background-color:#dcdcff'>##ever </span> <span style='background-color:#ffdede'>- </span> <span style='background-color:#ffe8e8'>efficacy </span> <span style='background-color:#fcfcff'>, </span> <span style='background-color:#ffecec'>safety </span> <span style='background-color:#fefeff'>, </span> <span style='background-color:#ffacac'>health </span> <span style='background-color:#ffa2a2'>economics </span> <span style='background-color:#ff6060'>, </span> <span style='background-color:#c8c8ff'>translation </span> <span style='background-color:#ffecec'>##al </span> <span style='background-color:#ffdede'>research </span> <span style='background-color:#ffcaca'>; </span> <span style='background-color:#ffb3b3'>summary </span> <span style='background-color:#ffd2d2'>: </span> <span style='background-color:#ffdede'>the </span> <span style='background-color:#dadaff'>present </span> <span style='background-color:#e6e6ff'>multi </span> <span style='background-color:#dadaff'>- </span> <span style='background-color:#f8f8ff'>center </span> <span style='background-color:#fff0f0'>, </span> <span style='background-color:#f3f3ff'>open </span> <span style='background-color:#d3d3ff'>- </span> <span style='background-color:#e6e6ff'>label </span> <span style='background-color:#e0e0ff'>, </span> <span style='background-color:#eeeeff'>single </span> <span style='background-color:#eeeeff'>- </span> <span style='background-color:#f0f0ff'>arm </span> <span style='background-color:#acacff'>study </span> <span style='background-color:#dadaff'>aims </span> <span style='background-color:#f8f8ff'>to </span> <span style='background-color:#ffe8e8'>evaluate </span> <span style='background-color:#eaeaff'>the </span> <span style='background-color:#e8e8ff'>efficacy </span> <span style='background-color:#fff6f6'>and </span> <span style='background-color:#ffe0e0'>safety </span> <span style='background-color:#c6c6ff'>, </span> <span style='background-color:#fff0f0'>quality </span> <span style='background-color:#fff4f4'>of </span> <span style='background-color:#ececff'>life </span> <span style='background-color:#c8c8ff'>and </span> <span style='background-color:#e0e0ff'>health </span> <span style='background-color:#ffbebe'>resources </span> <span style='background-color:#fffafa'>utilization </span> <span style='background-color:#fff8f8'>in </span> <span style='background-color:#f3f3ff'>post </span> <span style='background-color:#fff6f6'>##men </span> <span style='background-color:#fffcfc'>##opa </span> <span style='background-color:#ffe2e2'>##usa </span> <span style='background-color:#c6c6ff'>##l </span> <span style='background-color:#fff0f0'>women </span> <span style='background-color:#ffcaca'>with </span> <span style='background-color:#e0e0ff'>hormone </span> <span style='background-color:#a3a3ff'>receptor </span> <span style='background-color:#aaaaff'>positive </span> <span style='background-color:#e8e8ff'>breast </span> <span style='background-color:#fff8f8'>cancer </span> <span style='background-color:#fcfcff'>progressing </span> <span style='background-color:#d2d2ff'>following </span> <span style='background-color:#fcfcff'>prior </span> <span style='background-color:#ececff'>therapy </span> <span style='background-color:#eeeeff'>with </span> <span style='background-color:#fefeff'>non </span> <span style='background-color:#d8d8ff'>- </span> <span style='background-color:#d6d6ff'>ste </span> <span style='background-color:#e0e0ff'>##roid </span> <span style='background-color:#fff6f6'>##al </span> <span style='background-color:#aaaaff'>aroma </span> <span style='background-color:#fcfcff'>##tase </span> <span style='background-color:#cacaff'>inhibitors </span> <span style='background-color:#fff2f2'>( </span> <span style='background-color:#9e9eff'>nsa </span> <span style='background-color:#ececff'>##i </span> <span style='background-color:#b6b6ff'>) </span> <span style='background-color:#ffd2d2'>treated </span> <span style='background-color:#c8c8ff'>with </span> <span style='background-color:#f6f6ff'>the </span> <span style='background-color:#ffe4e4'>combination </span> <span style='background-color:#c6c6ff'>of </span> <span style='background-color:#ffe0e0'>ever </span> <span style='background-color:#ffa2a2'>##oli </span> <span style='background-color:#ffd2d2'>##mus </span> <span style='background-color:#f8f8ff'>and </span> <span style='background-color:#ccccff'>ex </span> <span style='background-color:#ffe6e6'>##eme </span> <span style='background-color:#f0f0ff'>##stan </span> <span style='background-color:#ffcaca'>##e </span> <span style='background-color:#ffe6e6'>. </span> <span style='background-color:#dcdcff'>; </span> <span style='background-color:#fff6f6'>phase </span> <span style='background-color:#e0e0ff'>: </span> <span style='background-color:#ffb6b6'>phase </span> <span style='background-color:#eaeaff'>3 </span> <span style='background-color:#ff3131'>[SEP] </span>"},"metadata":{}},{"name":"stdout","text":"\n\n","output_type":"stream"},{"output_type":"display_data","data":{"text/plain":"<IPython.core.display.HTML object>","text/html":"<span style='background-color:#f3f3ff'>[CLS] </span> <span style='background-color:#ff9898'>title </span> <span style='background-color:#f2f2ff'>: </span> <span style='background-color:#ff2121'>a </span> <span style='background-color:#ffaaaa'>multi </span> <span style='background-color:#ff6060'>##cent </span> <span style='background-color:#ff8a8a'>##er </span> <span style='background-color:#ff7474'>, </span> <span style='background-color:#bebeff'>random </span> <span style='background-color:#ceceff'>##ized </span> <span style='background-color:#ffc3c3'>, </span> <span style='background-color:#e0e0ff'>double </span> <span style='background-color:#ffe2e2'>- </span> <span style='background-color:#ffe6e6'>blind </span> <span style='background-color:#ffecec'>, </span> <span style='background-color:#eeeeff'>' </span> <span style='background-color:#fffefe'>crossover </span> <span style='background-color:#ffcccc'>' </span> <span style='background-color:#8383ff'>design </span> <span style='background-color:#f8f8ff'>study </span> <span style='background-color:#ffd0d0'>to </span> <span style='background-color:#ffe6e6'>evaluate </span> <span style='background-color:#ff7474'>the </span> <span style='background-color:#9e9eff'>lip </span> <span style='background-color:#ffc0c0'>##id </span> <span style='background-color:#c0c0ff'>- </span> <span style='background-color:#f6f6ff'>altering </span> <span style='background-color:#dedeff'>efficacy </span> <span style='background-color:#ffe4e4'>and </span> <span style='background-color:#ffb6b6'>safety </span> <span style='background-color:#eeeeff'>of </span> <span style='background-color:#fefeff'>mk </span> <span style='background-color:#fefeff'>- </span> <span style='background-color:#f8f8ff'>05 </span> <span style='background-color:#a3a3ff'>##24 </span> <span style='background-color:#a3a3ff'>##b </span> <span style='background-color:#ff6666'>combination </span> <span style='background-color:#ff0000'>tablet </span> <span style='background-color:#ffa2a2'>compared </span> <span style='background-color:#fff0f0'>to </span> <span style='background-color:#e3e3ff'>mk </span> <span style='background-color:#ffd8d8'>- </span> <span style='background-color:#7676ff'>05 </span> <span style='background-color:#ffcccc'>##24 </span> <span style='background-color:#ffdede'>##a </span> <span style='background-color:#fcfcff'>+ </span> <span style='background-color:#fff4f4'>sim </span> <span style='background-color:#ffdada'>##vas </span> <span style='background-color:#ffa3a3'>##tat </span> <span style='background-color:#b0b0ff'>##in </span> <span style='background-color:#ececff'>coa </span> <span style='background-color:#f0f0ff'>##dm </span> <span style='background-color:#ffdcdc'>##ini </span> <span style='background-color:#ffcece'>##stra </span> <span style='background-color:#fffefe'>##tion </span> <span style='background-color:#ffe4e4'>in </span> <span style='background-color:#fff4f4'>patients </span> <span style='background-color:#ffd0d0'>with </span> <span style='background-color:#f8f8ff'>primary </span> <span style='background-color:#ffdada'>hyper </span> <span style='background-color:#ffe4e4'>##cho </span> <span style='background-color:#ffeeee'>##les </span> <span style='background-color:#ffcccc'>##terol </span> <span style='background-color:#f2f2ff'>##emia </span> <span style='background-color:#fff2f2'>and </span> <span style='background-color:#fffefe'>mixed </span> <span style='background-color:#f0f0ff'>d </span> <span style='background-color:#ffe2e2'>##ys </span> <span style='background-color:#fffcfc'>##lip </span> <span style='background-color:#f0f0ff'>##ide </span> <span style='background-color:#ffeeee'>##mia </span> <span style='background-color:#ffeaea'>; </span> <span style='background-color:#dedeff'>summary </span> <span style='background-color:#fcfcff'>: </span> <span style='background-color:#8c8cff'>this </span> <span style='background-color:#c6c6ff'>is </span> <span style='background-color:#8686ff'>a </span> <span style='background-color:#ffd6d6'>20 </span> <span style='background-color:#e2e2ff'>- </span> <span style='background-color:#ffaeae'>week </span> <span style='background-color:#fffcfc'>clinical </span> <span style='background-color:#d8d8ff'>trial </span> <span style='background-color:#ffc8c8'>in </span> <span style='background-color:#c3c3ff'>participants </span> <span style='background-color:#fff6f6'>with </span> <span style='background-color:#f3f3ff'>primary </span> <span style='background-color:#fffcfc'>hyper </span> <span style='background-color:#fff6f6'>##cho </span> <span style='background-color:#ccccff'>##les </span> <span style='background-color:#e8e8ff'>##terol </span> <span style='background-color:#9393ff'>##emia </span> <span style='background-color:#ffe8e8'>or </span> <span style='background-color:#eaeaff'>mixed </span> <span style='background-color:#fff4f4'>d </span> <span style='background-color:#eeeeff'>##ys </span> <span style='background-color:#fffefe'>##lip </span> <span style='background-color:#ffeeee'>##ide </span> <span style='background-color:#ffb3b3'>##mia </span> <span style='background-color:#d0d0ff'>to </span> <span style='background-color:#fffafa'>demonstrate </span> <span style='background-color:#dadaff'>the </span> <span style='background-color:#fff6f6'>effect </span> <span style='background-color:#fff2f2'>of </span> <span style='background-color:#f0f0ff'>mk </span> <span style='background-color:#e2e2ff'>- </span> <span style='background-color:#f8f8ff'>05 </span> <span style='background-color:#f6f6ff'>##24 </span> <span style='background-color:#f2f2ff'>##b </span> <span style='background-color:#ffe6e6'>compared </span> <span style='background-color:#ffe8e8'>to </span> <span style='background-color:#fefeff'>mk </span> <span style='background-color:#d2d2ff'>- </span> <span style='background-color:#eeeeff'>05 </span> <span style='background-color:#fefeff'>##24 </span> <span style='background-color:#ffe4e4'>##a </span> <span style='background-color:#e3e3ff'>+ </span> <span style='background-color:#f8f8ff'>sim </span> <span style='background-color:#ffa3a3'>##vas </span> <span style='background-color:#ffb2b2'>##tat </span> <span style='background-color:#f6f6ff'>##in </span> <span style='background-color:#7171ff'>on </span> <span style='background-color:#f3f3ff'>lip </span> <span style='background-color:#ffaaaa'>##id </span> <span style='background-color:#e2e2ff'>values </span> <span style='background-color:#e8e8ff'>. </span> <span style='background-color:#cacaff'>; </span> <span style='background-color:#fffcfc'>phase </span> <span style='background-color:#dcdcff'>: </span> <span style='background-color:#ffc8c8'>phase </span> <span style='background-color:#dadaff'>3 </span> <span style='background-color:#fffcfc'>[SEP] </span>"},"metadata":{}},{"name":"stdout","text":"\n\n","output_type":"stream"},{"output_type":"display_data","data":{"text/plain":"<IPython.core.display.HTML object>","text/html":"<span style='background-color:#ffecec'>[CLS] </span> <span style='background-color:#ffb8b8'>title </span> <span style='background-color:#ffaaaa'>: </span> <span style='background-color:#f0f0ff'>a </span> <span style='background-color:#ffa8a8'>multi </span> <span style='background-color:#ffe4e4'>##cent </span> <span style='background-color:#fafaff'>##er </span> <span style='background-color:#ff8c8c'>, </span> <span style='background-color:#eaeaff'>random </span> <span style='background-color:#ececff'>##ized </span> <span style='background-color:#f2f2ff'>, </span> <span style='background-color:#fffefe'>double </span> <span style='background-color:#dadaff'>- </span> <span style='background-color:#f3f3ff'>blind </span> <span style='background-color:#ffe8e8'>, </span> <span style='background-color:#fff8f8'>phase </span> <span style='background-color:#f0f0ff'>iii </span> <span style='background-color:#ffd6d6'>trial </span> <span style='background-color:#ffdede'>to </span> <span style='background-color:#fff4f4'>evaluate </span> <span style='background-color:#ffb6b6'>the </span> <span style='background-color:#ffeaea'>safety </span> <span style='background-color:#fefeff'>, </span> <span style='background-color:#ffbcbc'>im </span> <span style='background-color:#ffb6b6'>##mun </span> <span style='background-color:#e2e2ff'>##ogenic </span> <span style='background-color:#f3f3ff'>##ity </span> <span style='background-color:#fff4f4'>, </span> <span style='background-color:#ffd8d8'>and </span> <span style='background-color:#e3e3ff'>efficacy </span> <span style='background-color:#ffcaca'>of </span> <span style='background-color:#eaeaff'>ms </span> <span style='background-color:#ffd0d0'>##b </span> <span style='background-color:#f2f2ff'>##11 </span> <span style='background-color:#ffe6e6'>##0 </span> <span style='background-color:#ffcaca'>##22 </span> <span style='background-color:#ffc2c2'>compared </span> <span style='background-color:#ff8a8a'>with </span> <span style='background-color:#9292ff'>hum </span> <span style='background-color:#ff8686'>##ira </span> <span style='background-color:#ff9898'>##¬ </span> <span style='background-color:#b0b0ff'>##æ </span> <span style='background-color:#ffdede'>in </span> <span style='background-color:#ffcccc'>patients </span> <span style='background-color:#eeeeff'>with </span> <span style='background-color:#fffafa'>moderately </span> <span style='background-color:#fff2f2'>to </span> <span style='background-color:#eeeeff'>severely </span> <span style='background-color:#fffefe'>active </span> <span style='background-color:#ffdede'>r </span> <span style='background-color:#9696ff'>##he </span> <span style='background-color:#0000ff'>##uma </span> <span style='background-color:#a0a0ff'>##to </span> <span style='background-color:#fff0f0'>##id </span> <span style='background-color:#ffa3a3'>arthritis </span> <span style='background-color:#ff8a8a'>; </span> <span style='background-color:#acacff'>summary </span> <span style='background-color:#d0d0ff'>: </span> <span style='background-color:#ffe8e8'>the </span> <span style='background-color:#f3f3ff'>purpose </span> <span style='background-color:#aeaeff'>of </span> <span style='background-color:#f3f3ff'>this </span> <span style='background-color:#ffe8e8'>study </span> <span style='background-color:#f8f8ff'>is </span> <span style='background-color:#eaeaff'>to </span> <span style='background-color:#c8c8ff'>compare </span> <span style='background-color:#ffa2a2'>the </span> <span style='background-color:#e2e2ff'>efficacy </span> <span style='background-color:#fafaff'>, </span> <span style='background-color:#ffd2d2'>safety </span> <span style='background-color:#ffeeee'>and </span> <span style='background-color:#dcdcff'>im </span> <span style='background-color:#dadaff'>##mun </span> <span style='background-color:#bebeff'>##ogenic </span> <span style='background-color:#fffcfc'>##ity </span> <span style='background-color:#f6f6ff'>of </span> <span style='background-color:#ececff'>ms </span> <span style='background-color:#fefeff'>##b </span> <span style='background-color:#ffe0e0'>##11 </span> <span style='background-color:#fefeff'>##0 </span> <span style='background-color:#f8f8ff'>##22 </span> <span style='background-color:#e0e0ff'>and </span> <span style='background-color:#ffc8c8'>hum </span> <span style='background-color:#ff8888'>##ira </span> <span style='background-color:#f6f6ff'>##¬ </span> <span style='background-color:#6060ff'>##æ </span> <span style='background-color:#ffeeee'>in </span> <span style='background-color:#fafaff'>adult </span> <span style='background-color:#babaff'>subjects </span> <span style='background-color:#7e7eff'>with </span> <span style='background-color:#fffafa'>r </span> <span style='background-color:#a2a2ff'>##he </span> <span style='background-color:#bebeff'>##uma </span> <span style='background-color:#d6d6ff'>##to </span> <span style='background-color:#f3f3ff'>##id </span> <span style='background-color:#ececff'>arthritis </span> <span style='background-color:#ffa3a3'>. </span> <span style='background-color:#f3f3ff'>; </span> <span style='background-color:#d8d8ff'>phase </span> <span style='background-color:#e0e0ff'>: </span> <span style='background-color:#fafaff'>phase </span> <span style='background-color:#c8c8ff'>3 </span> <span style='background-color:#ff6161'>[SEP] </span>"},"metadata":{}},{"name":"stdout","text":"\n\n","output_type":"stream"},{"output_type":"display_data","data":{"text/plain":"<IPython.core.display.HTML object>","text/html":"<span style='background-color:#fff4f4'>[CLS] </span> <span style='background-color:#fff6f6'>title </span> <span style='background-color:#fff8f8'>: </span> <span style='background-color:#fff4f4'>a </span> <span style='background-color:#fffcfc'>multi </span> <span style='background-color:#fff4f4'>##cent </span> <span style='background-color:#fcfcff'>##er </span> <span style='background-color:#fff8f8'>, </span> <span style='background-color:#fffefe'>open </span> <span style='background-color:#fcfcff'>- </span> <span style='background-color:#fff6f6'>label </span> <span style='background-color:#fffcfc'>extension </span> <span style='background-color:#fffefe'>, </span> <span style='background-color:#fffefe'>multiple </span> <span style='background-color:#fefeff'>dose </span> <span style='background-color:#fffcfc'>, </span> <span style='background-color:#fcfcff'>parallel </span> <span style='background-color:#fffefe'>group </span> <span style='background-color:#fffefe'>study </span> <span style='background-color:#fffefe'>to </span> <span style='background-color:#fefeff'>investigate </span> <span style='background-color:#ffeaea'>the </span> <span style='background-color:#fffefe'>long </span> <span style='background-color:#fefeff'>- </span> <span style='background-color:#fffefe'>term </span> <span style='background-color:#fefeff'>safety </span> <span style='background-color:#fffefe'>and </span> <span style='background-color:#fffefe'>to </span> <span style='background-color:#fffefe'>##ler </span> <span style='background-color:#fffafa'>##ability </span> <span style='background-color:#fefeff'>of </span> <span style='background-color:#fcfcff'>aa </span> <span style='background-color:#fefeff'>##b </span> <span style='background-color:#fffafa'>- </span> <span style='background-color:#fcfcff'>00 </span> <span style='background-color:#fffcfc'>##3 </span> <span style='background-color:#fff8f8'>( </span> <span style='background-color:#fffcfc'>p </span> <span style='background-color:#fffcfc'>##f </span> <span style='background-color:#fffefe'>- </span> <span style='background-color:#fefeff'>05 </span> <span style='background-color:#fffcfc'>##23 </span> <span style='background-color:#fffefe'>##6 </span> <span style='background-color:#fffefe'>##8 </span> <span style='background-color:#fffefe'>##12 </span> <span style='background-color:#fffcfc'>) </span> <span style='background-color:#fefeff'>administered </span> <span style='background-color:#fffefe'>intra </span> <span style='background-color:#fffefe'>##ven </span> <span style='background-color:#fafaff'>##ously </span> <span style='background-color:#fffcfc'>in </span> <span style='background-color:#fffefe'>subjects </span> <span style='background-color:#fefeff'>with </span> <span style='background-color:#f8f8ff'>mild </span> <span style='background-color:#fffcfc'>to </span> <span style='background-color:#fffefe'>moderate </span> <span style='background-color:#fffafa'>alzheimer </span> <span style='background-color:#fffcfc'>' </span> <span style='background-color:#fffefe'>s </span> <span style='background-color:#f6f6ff'>disease </span> <span style='background-color:#f8f8ff'>previously </span> <span style='background-color:#fefeff'>treated </span> <span style='background-color:#fefeff'>with </span> <span style='background-color:#fafaff'>aa </span> <span style='background-color:#fffefe'>##b </span> <span style='background-color:#fefeff'>- </span> <span style='background-color:#fefeff'>00 </span> <span style='background-color:#fffafa'>##3 </span> <span style='background-color:#fffefe'>or </span> <span style='background-color:#fffcfc'>place </span> <span style='background-color:#fffcfc'>##bo </span> <span style='background-color:#fffefe'>in </span> <span style='background-color:#fffcfc'>protocol </span> <span style='background-color:#fafaff'>b </span> <span style='background-color:#fefeff'>##26 </span> <span style='background-color:#fefeff'>##01 </span> <span style='background-color:#fcfcff'>##00 </span> <span style='background-color:#fffcfc'>##1 </span> <span style='background-color:#f8f8ff'>; </span> <span style='background-color:#fffefe'>summary </span> <span style='background-color:#fffefe'>: </span> <span style='background-color:#fefeff'>this </span> <span style='background-color:#fcfcff'>is </span> <span style='background-color:#fefeff'>a </span> <span style='background-color:#fefeff'>study </span> <span style='background-color:#fcfcff'>to </span> <span style='background-color:#fefeff'>evaluate </span> <span style='background-color:#fafaff'>the </span> <span style='background-color:#fefeff'>safety </span> <span style='background-color:#fefeff'>and </span> <span style='background-color:#fffcfc'>to </span> <span style='background-color:#fffcfc'>##ler </span> <span style='background-color:#fffefe'>##ability </span> <span style='background-color:#fffefe'>of </span> <span style='background-color:#fafaff'>multiple </span> <span style='background-color:#f6f6ff'>doses </span> <span style='background-color:#fcfcff'>of </span> <span style='background-color:#fffefe'>aa </span> <span style='background-color:#fffcfc'>##b </span> <span style='background-color:#f8f8ff'>- </span> <span style='background-color:#fefeff'>00 </span> <span style='background-color:#fffcfc'>##3 </span> <span style='background-color:#fefeff'>( </span> <span style='background-color:#fefeff'>p </span> <span style='background-color:#fffefe'>##f </span> <span style='background-color:#fcfcff'>- </span> <span style='background-color:#fffefe'>05 </span> <span style='background-color:#fffefe'>##23 </span> <span style='background-color:#fefeff'>##6 </span> <span style='background-color:#fffefe'>##8 </span> <span style='background-color:#fefeff'>##12 </span> <span style='background-color:#fffefe'>) </span> <span style='background-color:#fefeff'>in </span> <span style='background-color:#fefeff'>patients </span> <span style='background-color:#fffefe'>with </span> <span style='background-color:#fcfcff'>mild </span> <span style='background-color:#fcfcff'>to </span> <span style='background-color:#fffafa'>moderate </span> <span style='background-color:#fffcfc'>alzheimer </span> <span style='background-color:#fefeff'>' </span> <span style='background-color:#f8f8ff'>s </span> <span style='background-color:#f3f3ff'>disease </span> <span style='background-color:#fefeff'>. </span> <span style='background-color:#fffefe'>patients </span> <span style='background-color:#fefeff'>who </span> <span style='background-color:#fffefe'>complete </span> <span style='background-color:#fefeff'>study </span> <span style='background-color:#fcfcff'>b </span> <span style='background-color:#fefeff'>##26 </span> <span style='background-color:#fff8f8'>##01 </span> <span style='background-color:#fafaff'>##00 </span> <span style='background-color:#fefeff'>##1 </span> <span style='background-color:#fefeff'>may </span> <span style='background-color:#fffcfc'>participate </span> <span style='background-color:#fafaff'>in </span> <span style='background-color:#fffcfc'>this </span> <span style='background-color:#fafaff'>trial </span> <span style='background-color:#fcfcff'>and </span> <span style='background-color:#fffcfc'>receive </span> <span style='background-color:#fffefe'>aa </span> <span style='background-color:#fefeff'>##b </span> <span style='background-color:#fcfcff'>- </span> <span style='background-color:#fffefe'>00 </span> <span style='background-color:#fffcfc'>##3 </span> <span style='background-color:#fffefe'>( </span> <span style='background-color:#fffcfc'>p </span> <span style='background-color:#fffefe'>##f </span> <span style='background-color:#fffefe'>- </span> <span style='background-color:#fffcfc'>05 </span> <span style='background-color:#fefeff'>##23 </span> <span style='background-color:#fffefe'>##6 </span> <span style='background-color:#fefeff'>##8 </span> <span style='background-color:#fffcfc'>##12 </span> <span style='background-color:#fffcfc'>) </span> <span style='background-color:#fafaff'>. </span> <span style='background-color:#fffafa'>each </span> <span style='background-color:#fcfcff'>patient </span> <span style='background-color:#fffcfc'>' </span> <span style='background-color:#fffafa'>s </span> <span style='background-color:#fff8f8'>participation </span> <span style='background-color:#fffefe'>will </span> <span style='background-color:#fffefe'>last </span> <span style='background-color:#fffefe'>approximately </span> <span style='background-color:#fffcfc'>52 </span> <span style='background-color:#fffefe'>weeks </span> <span style='background-color:#fffefe'>. </span> <span style='background-color:#fafaff'>; </span> <span style='background-color:#fffafa'>phase </span> <span style='background-color:#fefeff'>: </span> <span style='background-color:#fffafa'>phase </span> <span style='background-color:#fff8f8'>1 </span> <span style='background-color:#0000ff'>[SEP] </span>"},"metadata":{}},{"name":"stdout","text":"\n\n","output_type":"stream"},{"output_type":"display_data","data":{"text/plain":"<IPython.core.display.HTML object>","text/html":"<span style='background-color:#ffecec'>[CLS] </span> <span style='background-color:#ffa6a6'>title </span> <span style='background-color:#ffe2e2'>: </span> <span style='background-color:#fff2f2'>a </span> <span style='background-color:#ffbcbc'>phase </span> <span style='background-color:#ffaaaa'>iii </span> <span style='background-color:#fefeff'>random </span> <span style='background-color:#fafaff'>##ized </span> <span style='background-color:#ffecec'>, </span> <span style='background-color:#fff6f6'>double </span> <span style='background-color:#e3e3ff'>- </span> <span style='background-color:#fffafa'>blind </span> <span style='background-color:#fff4f4'>, </span> <span style='background-color:#fafaff'>controlled </span> <span style='background-color:#eaeaff'>study </span> <span style='background-color:#f3f3ff'>comparing </span> <span style='background-color:#ffcece'>cl </span> <span style='background-color:#ccccff'>##of </span> <span style='background-color:#ffacac'>##ara </span> <span style='background-color:#dedeff'>##bine </span> <span style='background-color:#ffdada'>and </span> <span style='background-color:#f0f0ff'>cy </span> <span style='background-color:#ffeeee'>##tara </span> <span style='background-color:#fffefe'>##bine </span> <span style='background-color:#fff4f4'>versus </span> <span style='background-color:#fff6f6'>cy </span> <span style='background-color:#ffe8e8'>##tara </span> <span style='background-color:#fcfcff'>##bine </span> <span style='background-color:#fffefe'>alone </span> <span style='background-color:#fafaff'>in </span> <span style='background-color:#fff8f8'>adult </span> <span style='background-color:#fff2f2'>patients </span> <span style='background-color:#fff4f4'>55 </span> <span style='background-color:#fefeff'>years </span> <span style='background-color:#fffefe'>and </span> <span style='background-color:#fafaff'>older </span> <span style='background-color:#fefeff'>with </span> <span style='background-color:#fff4f4'>acute </span> <span style='background-color:#fffcfc'>my </span> <span style='background-color:#fcfcff'>##elo </span> <span style='background-color:#ffeaea'>##gen </span> <span style='background-color:#f3f3ff'>##ous </span> <span style='background-color:#ececff'>leukemia </span> <span style='background-color:#ececff'>( </span> <span style='background-color:#f2f2ff'>am </span> <span style='background-color:#fffafa'>##l </span> <span style='background-color:#f3f3ff'>) </span> <span style='background-color:#fffcfc'>who </span> <span style='background-color:#f8f8ff'>have </span> <span style='background-color:#f3f3ff'>re </span> <span style='background-color:#fffcfc'>##la </span> <span style='background-color:#eeeeff'>##pse </span> <span style='background-color:#fafaff'>##d </span> <span style='background-color:#fefeff'>or </span> <span style='background-color:#fefeff'>are </span> <span style='background-color:#fffcfc'>ref </span> <span style='background-color:#fcfcff'>##rac </span> <span style='background-color:#fffafa'>##tory </span> <span style='background-color:#fafaff'>after </span> <span style='background-color:#fffcfc'>receiving </span> <span style='background-color:#fff6f6'>up </span> <span style='background-color:#eeeeff'>to </span> <span style='background-color:#fffcfc'>two </span> <span style='background-color:#fcfcff'>prior </span> <span style='background-color:#fffafa'>induction </span> <span style='background-color:#eeeeff'>regime </span> <span style='background-color:#ffeeee'>##ns </span> <span style='background-color:#e0e0ff'>; </span> <span style='background-color:#fff4f4'>summary </span> <span style='background-color:#dedeff'>: </span> <span style='background-color:#ffeaea'>cl </span> <span style='background-color:#f8f8ff'>##of </span> <span style='background-color:#fffafa'>##ara </span> <span style='background-color:#f6f6ff'>##bine </span> <span style='background-color:#f3f3ff'>( </span> <span style='background-color:#fffefe'>injection </span> <span style='background-color:#fff4f4'>) </span> <span style='background-color:#f8f8ff'>is </span> <span style='background-color:#fafaff'>approved </span> <span style='background-color:#ffeaea'>by </span> <span style='background-color:#ffe8e8'>the </span> <span style='background-color:#fffafa'>food </span> <span style='background-color:#fff8f8'>and </span> <span style='background-color:#fffafa'>drug </span> <span style='background-color:#fff0f0'>administration </span> <span style='background-color:#ffe4e4'>( </span> <span style='background-color:#fafaff'>fda </span> <span style='background-color:#fefeff'>) </span> <span style='background-color:#fff8f8'>for </span> <span style='background-color:#f8f8ff'>the </span> <span style='background-color:#f0f0ff'>treatment </span> <span style='background-color:#ececff'>of </span> <span style='background-color:#e8e8ff'>pediatric </span> <span style='background-color:#fafaff'>patients </span> <span style='background-color:#f2f2ff'>1 </span> <span style='background-color:#ffeaea'>to </span> <span style='background-color:#fafaff'>21 </span> <span style='background-color:#f6f6ff'>years </span> <span style='background-color:#fefeff'>old </span> <span style='background-color:#f3f3ff'>with </span> <span style='background-color:#f8f8ff'>re </span> <span style='background-color:#fff8f8'>##la </span> <span style='background-color:#f8f8ff'>##pse </span> <span style='background-color:#fffefe'>##d </span> <span style='background-color:#f8f8ff'>acute </span> <span style='background-color:#fafaff'>or </span> <span style='background-color:#f3f3ff'>ref </span> <span style='background-color:#f8f8ff'>##rac </span> <span style='background-color:#fffcfc'>##tory </span> <span style='background-color:#e3e3ff'>l </span> <span style='background-color:#e3e3ff'>##ym </span> <span style='background-color:#e0e0ff'>##ph </span> <span style='background-color:#eeeeff'>##ob </span> <span style='background-color:#f8f8ff'>##lastic </span> <span style='background-color:#f6f6ff'>leukemia </span> <span style='background-color:#f3f3ff'>( </span> <span style='background-color:#e3e3ff'>all </span> <span style='background-color:#e6e6ff'>) </span> <span style='background-color:#e0e0ff'>who </span> <span style='background-color:#f2f2ff'>have </span> <span style='background-color:#dedeff'>had </span> <span style='background-color:#fafaff'>at </span> <span style='background-color:#e0e0ff'>least </span> <span style='background-color:#e8e8ff'>2 </span> <span style='background-color:#f0f0ff'>prior </span> <span style='background-color:#dedeff'>treatment </span> <span style='background-color:#dcdcff'>regime </span> <span style='background-color:#f8f8ff'>##ns </span> <span style='background-color:#d6d6ff'>. </span> <span style='background-color:#c2c2ff'>there </span> <span style='background-color:#fff4f4'>is </span> <span style='background-color:#f6f6ff'>no </span> <span style='background-color:#fffafa'>recommended </span> <span style='background-color:#fff8f8'>standard </span> <span style='background-color:#fff0f0'>treatment </span> <span style='background-color:#fafaff'>for </span> <span style='background-color:#fff2f2'>re </span> <span style='background-color:#fff2f2'>##la </span> <span style='background-color:#fefeff'>##pse </span> <span style='background-color:#fff4f4'>##d </span> <span style='background-color:#f6f6ff'>or </span> <span style='background-color:#fffcfc'>ref </span> <span style='background-color:#fff6f6'>##rac </span> <span style='background-color:#ffe8e8'>##tory </span> <span style='background-color:#f3f3ff'>acute </span> <span style='background-color:#fff4f4'>my </span> <span style='background-color:#fff0f0'>##elo </span> <span style='background-color:#fffafa'>##gen </span> <span style='background-color:#fefeff'>##ous </span> <span style='background-color:#fffcfc'>leukemia </span> <span style='background-color:#fff6f6'>in </span> <span style='background-color:#fffcfc'>older </span> <span style='background-color:#fffcfc'>patients </span> <span style='background-color:#e8e8ff'>. </span> <span style='background-color:#fff0f0'>cy </span> <span style='background-color:#ffdede'>##tara </span> <span style='background-color:#fff6f6'>##bine </span> <span style='background-color:#fefeff'>is </span> <span style='background-color:#fafaff'>the </span> <span style='background-color:#fffefe'>most </span> <span style='background-color:#f3f3ff'>commonly </span> <span style='background-color:#fafaff'>used </span> <span style='background-color:#f8f8ff'>drug </span> <span style='background-color:#fcfcff'>to </span> <span style='background-color:#fff8f8'>treat </span> <span style='background-color:#fffcfc'>these </span> <span style='background-color:#fffefe'>patients </span> <span style='background-color:#f2f2ff'>. </span> <span style='background-color:#fcfcff'>this </span> <span style='background-color:#f8f8ff'>study </span> <span style='background-color:#f6f6ff'>will </span> <span style='background-color:#fefeff'>determine </span> <span style='background-color:#fffcfc'>if </span> <span style='background-color:#fafaff'>there </span> <span style='background-color:#fefeff'>is </span> <span style='background-color:#fefeff'>benefit </span> <span style='background-color:#fffcfc'>by </span> <span style='background-color:#f2f2ff'>combining </span> <span style='background-color:#ffeeee'>cl </span> <span style='background-color:#f6f6ff'>##of </span> <span style='background-color:#ffdcdc'>##ara </span> <span style='background-color:#fff2f2'>##bine </span> <span style='background-color:#e8e8ff'>with </span> <span style='background-color:#fffefe'>cy </span> <span style='background-color:#ffe8e8'>##tara </span> <span style='background-color:#fff0f0'>##bine </span> <span style='background-color:#f3f3ff'>. </span> <span style='background-color:#fefeff'>patients </span> <span style='background-color:#fffefe'>will </span> <span style='background-color:#fffafa'>be </span> <span style='background-color:#fffafa'>random </span> <span style='background-color:#fffafa'>##ized </span> <span style='background-color:#fcfcff'>to </span> <span style='background-color:#fffafa'>receive </span> <span style='background-color:#fff6f6'>up </span> <span style='background-color:#fcfcff'>to </span> <span style='background-color:#fffefe'>3 </span> <span style='background-color:#fefeff'>cycles </span> <span style='background-color:#fffcfc'>of </span> <span style='background-color:#fff6f6'>treatment </span> <span style='background-color:#fefeff'>with </span> <span style='background-color:#fafaff'>either </span> <span style='background-color:#fcfcff'>place </span> <span style='background-color:#fefeff'>##bo </span> <span style='background-color:#fffefe'>in </span> <span style='background-color:#fffefe'>combination </span> <span style='background-color:#fffefe'>with </span> <span style='background-color:#ffeeee'>cy </span> <span style='background-color:#fff0f0'>##tara </span> <span style='background-color:#ffeeee'>##bine </span> <span style='background-color:#fff8f8'>or </span> <span style='background-color:#ffeeee'>cl </span> <span style='background-color:#fff4f4'>##of </span> <span style='background-color:#fff2f2'>##ara </span> <span style='background-color:#f0f0ff'>##bine </span> <span style='background-color:#f2f2ff'>in </span> <span style='background-color:#fffcfc'>combination </span> <span style='background-color:#eeeeff'>with </span> <span style='background-color:#fafaff'>cy </span> <span style='background-color:#ffe2e2'>##tara </span> <span style='background-color:#fafaff'>##bine </span> <span style='background-color:#f8f8ff'>. </span> <span style='background-color:#fffafa'>random </span> <span style='background-color:#ffecec'>##ization </span> <span style='background-color:#fcfcff'>was </span> <span style='background-color:#fffcfc'>st </span> <span style='background-color:#fffafa'>##rat </span> <span style='background-color:#fffcfc'>##ified </span> <span style='background-color:#fcfcff'>by </span> <span style='background-color:#fffafa'>re </span> <span style='background-color:#fffafa'>##mission </span> <span style='background-color:#fffcfc'>status </span> <span style='background-color:#fefeff'>following </span> <span style='background-color:#ffdcdc'>the </span> <span style='background-color:#fff8f8'>first </span> <span style='background-color:#fffcfc'>induction </span> <span style='background-color:#fff4f4'>regime </span> <span style='background-color:#fefeff'>##n </span> <span style='background-color:#fff6f6'>( </span> <span style='background-color:#fefeff'>no </span> <span style='background-color:#fefeff'>re </span> <span style='background-color:#fafaff'>##mission </span> <span style='background-color:#f8f8ff'>[ </span> <span style='background-color:#fcfcff'>i </span> <span style='background-color:#fafaff'>. </span> <span style='background-color:#fffafa'>e </span> <span style='background-color:#f6f6ff'>. </span> <span style='background-color:#fefeff'>, </span> <span style='background-color:#ffe8e8'>cr </span> <span style='background-color:#fffafa'>##1 </span> <span style='background-color:#fffefe'>= </span> <span style='background-color:#fefeff'>ref </span> <span style='background-color:#fffcfc'>##rac </span> <span style='background-color:#ffeaea'>##tory </span> <span style='background-color:#ffeeee'>] </span> <span style='background-color:#fff8f8'>or </span> <span style='background-color:#ffe0e0'>re </span> <span style='background-color:#f8f8ff'>##mission </span> <span style='background-color:#fff0f0'>< </span> <span style='background-color:#fffafa'>6 </span> <span style='background-color:#fff0f0'>months </span> <span style='background-color:#fefeff'>vs </span> <span style='background-color:#fffcfc'>cr </span> <span style='background-color:#fff8f8'>##1 </span> <span style='background-color:#f6f6ff'>= </span> <span style='background-color:#fcfcff'>re </span> <span style='background-color:#fffafa'>##mission </span> <span style='background-color:#fffcfc'>‚ </span> <span style='background-color:#ffe0e0'>a </span> <span style='background-color:#ffe6e6'>• </span> <span style='background-color:#fff6f6'>6 </span> <span style='background-color:#fff4f4'>months </span> <span style='background-color:#fffefe'>) </span> <span style='background-color:#fff6f6'>. </span> <span style='background-color:#ffe8e8'>cr </span> <span style='background-color:#fefeff'>##1 </span> <span style='background-color:#fffefe'>is </span> <span style='background-color:#fffcfc'>defined </span> <span style='background-color:#fffcfc'>as </span> <span style='background-color:#fefeff'>re </span> <span style='background-color:#fefeff'>##mission </span> <span style='background-color:#f8f8ff'>after </span> <span style='background-color:#fffcfc'>first </span> <span style='background-color:#fff8f8'>pre </span> <span style='background-color:#f0f0ff'>- </span> <span style='background-color:#ffe6e6'>study </span> <span style='background-color:#fefeff'>induction </span> <span style='background-color:#fcfcff'>regime </span> <span style='background-color:#fff6f6'>##n </span> <span style='background-color:#f3f3ff'>. </span> <span style='background-color:#ffeeee'>the </span> <span style='background-color:#fefeff'>safety </span> <span style='background-color:#fffafa'>and </span> <span style='background-color:#fefeff'>to </span> <span style='background-color:#fffafa'>##ler </span> <span style='background-color:#fefeff'>##ability </span> <span style='background-color:#fcfcff'>of </span> <span style='background-color:#ffeaea'>cl </span> <span style='background-color:#ffe6e6'>##of </span> <span style='background-color:#ffdede'>##ara </span> <span style='background-color:#fffcfc'>##bine </span> <span style='background-color:#fff8f8'>in </span> <span style='background-color:#fffefe'>combination </span> <span style='background-color:#f2f2ff'>with </span> <span style='background-color:#fffcfc'>cy </span> <span style='background-color:#ffe2e2'>##tara </span> <span style='background-color:#fefeff'>##bine </span> <span style='background-color:#f8f8ff'>and </span> <span style='background-color:#fffefe'>cy </span> <span style='background-color:#f8f8ff'>##tara </span> <span style='background-color:#ffe4e4'>##bine </span> <span style='background-color:#fffafa'>alone </span> <span style='background-color:#f8f8ff'>will </span> <span style='background-color:#f8f8ff'>be </span> <span style='background-color:#fff0f0'>monitored </span> <span style='background-color:#fffefe'>throughout </span> <span style='background-color:#fffafa'>the </span> <span style='background-color:#fff8f8'>study </span> <span style='background-color:#fffefe'>. </span> <span style='background-color:#fffafa'>; </span> <span style='background-color:#fffafa'>phase </span> <span style='background-color:#fffafa'>: </span> <span style='background-color:#ffdada'>phase </span> <span style='background-color:#d6d6ff'>3 </span> <span style='background-color:#0000ff'>[SEP] </span>"},"metadata":{}},{"name":"stdout","text":"\n\n","output_type":"stream"},{"output_type":"display_data","data":{"text/plain":"<IPython.core.display.HTML object>","text/html":"<span style='background-color:#ff8080'>[CLS] </span> <span style='background-color:#ff0000'>title </span> <span style='background-color:#ffbebe'>: </span> <span style='background-color:#ffa3a3'>a </span> <span style='background-color:#ffd0d0'>phase </span> <span style='background-color:#ffeaea'>2 </span> <span style='background-color:#ffe0e0'>multi </span> <span style='background-color:#ff9c9c'>- </span> <span style='background-color:#ff9696'>centre </span> <span style='background-color:#ffe0e0'>, </span> <span style='background-color:#8282ff'>random </span> <span style='background-color:#ccccff'>##ised </span> <span style='background-color:#fafaff'>, </span> <span style='background-color:#dcdcff'>double </span> <span style='background-color:#dedeff'>- </span> <span style='background-color:#f3f3ff'>blind </span> <span style='background-color:#fcfcff'>, </span> <span style='background-color:#fffefe'>place </span> <span style='background-color:#fcfcff'>##bo </span> <span style='background-color:#f2f2ff'>controlled </span> <span style='background-color:#fff6f6'>, </span> <span style='background-color:#ffe2e2'>dose </span> <span style='background-color:#ffeeee'>ranging </span> <span style='background-color:#e0e0ff'>study </span> <span style='background-color:#fffcfc'>of </span> <span style='background-color:#bcbcff'>tb </span> <span style='background-color:#ffacac'>##c </span> <span style='background-color:#c3c3ff'>##37 </span> <span style='background-color:#ffcece'>##11 </span> <span style='background-color:#bebeff'>in </span> <span style='background-color:#d8d8ff'>subjects </span> <span style='background-color:#ffe0e0'>with </span> <span style='background-color:#babaff'>resistant </span> <span style='background-color:#e6e6ff'>hyper </span> <span style='background-color:#d6d6ff'>##tension </span> <span style='background-color:#ffd6d6'>; </span> <span style='background-color:#dcdcff'>summary </span> <span style='background-color:#ffeeee'>: </span> <span style='background-color:#ff9696'>the </span> <span style='background-color:#fefeff'>study </span> <span style='background-color:#fcfcff'>was </span> <span style='background-color:#ffd8d8'>to </span> <span style='background-color:#f8f8ff'>determine </span> <span style='background-color:#ff7878'>the </span> <span style='background-color:#f8f8ff'>safe </span> <span style='background-color:#ffe0e0'>and </span> <span style='background-color:#dadaff'>effective </span> <span style='background-color:#cacaff'>dose </span> <span style='background-color:#fff4f4'>of </span> <span style='background-color:#6464ff'>tb </span> <span style='background-color:#ff8c8c'>##c </span> <span style='background-color:#d6d6ff'>##37 </span> <span style='background-color:#ffcccc'>##11 </span> <span style='background-color:#babaff'>in </span> <span style='background-color:#e2e2ff'>patients </span> <span style='background-color:#d8d8ff'>with </span> <span style='background-color:#c2c2ff'>un </span> <span style='background-color:#d0d0ff'>##con </span> <span style='background-color:#e3e3ff'>##tro </span> <span style='background-color:#aaaaff'>##lled </span> <span style='background-color:#ffe4e4'>high </span> <span style='background-color:#7878ff'>blood </span> <span style='background-color:#c3c3ff'>pressure </span> <span style='background-color:#dadaff'>while </span> <span style='background-color:#e6e6ff'>already </span> <span style='background-color:#cacaff'>taking </span> <span style='background-color:#d6d6ff'>blood </span> <span style='background-color:#fefeff'>pressure </span> <span style='background-color:#fffcfc'>medications </span> <span style='background-color:#e2e2ff'>. </span> <span style='background-color:#cacaff'>; </span> <span style='background-color:#fffafa'>phase </span> <span style='background-color:#dedeff'>: </span> <span style='background-color:#eaeaff'>phase </span> <span style='background-color:#e8e8ff'>2 </span> <span style='background-color:#8686ff'>[SEP] </span>"},"metadata":{}},{"name":"stdout","text":"\n\n","output_type":"stream"},{"output_type":"display_data","data":{"text/plain":"<IPython.core.display.HTML object>","text/html":"<span style='background-color:#fafaff'>[CLS] </span> <span style='background-color:#fff6f6'>title </span> <span style='background-color:#fff4f4'>: </span> <span style='background-color:#fafaff'>a </span> <span style='background-color:#fffefe'>multi </span> <span style='background-color:#fff8f8'>##cent </span> <span style='background-color:#fcfcff'>##er </span> <span style='background-color:#fff6f6'>, </span> <span style='background-color:#fefeff'>open </span> <span style='background-color:#fffefe'>label </span> <span style='background-color:#fffafa'>, </span> <span style='background-color:#fffefe'>phase </span> <span style='background-color:#fffefe'>1b </span> <span style='background-color:#f0f0ff'>study </span> <span style='background-color:#fcfcff'>of </span> <span style='background-color:#fffefe'>es </span> <span style='background-color:#f8f8ff'>##cala </span> <span style='background-color:#f3f3ff'>##ting </span> <span style='background-color:#f2f2ff'>doses </span> <span style='background-color:#fefeff'>of </span> <span style='background-color:#fff8f8'>ro </span> <span style='background-color:#f2f2ff'>##50 </span> <span style='background-color:#fff4f4'>##45 </span> <span style='background-color:#fffefe'>##33 </span> <span style='background-color:#fafaff'>##7 </span> <span style='background-color:#fafaff'>administered </span> <span style='background-color:#fffefe'>oral </span> <span style='background-color:#fffcfc'>##ly </span> <span style='background-color:#eaeaff'>, </span> <span style='background-color:#fff6f6'>with </span> <span style='background-color:#fff8f8'>cy </span> <span style='background-color:#ffe4e4'>##tara </span> <span style='background-color:#fafaff'>##bine </span> <span style='background-color:#fcfcff'>administered </span> <span style='background-color:#eeeeff'>a </span> <span style='background-color:#fff6f6'>) </span> <span style='background-color:#fffefe'>sub </span> <span style='background-color:#fffcfc'>##cut </span> <span style='background-color:#fffafa'>##aneous </span> <span style='background-color:#fffcfc'>##ly </span> <span style='background-color:#fefeff'>, </span> <span style='background-color:#fafaff'>or </span> <span style='background-color:#fafaff'>b </span> <span style='background-color:#fffcfc'>) </span> <span style='background-color:#fefeff'>intra </span> <span style='background-color:#fffafa'>##ven </span> <span style='background-color:#fff4f4'>##ously </span> <span style='background-color:#fcfcff'>, </span> <span style='background-color:#fffafa'>in </span> <span style='background-color:#ececff'>patients </span> <span style='background-color:#fafaff'>with </span> <span style='background-color:#f6f6ff'>acute </span> <span style='background-color:#f3f3ff'>my </span> <span style='background-color:#f3f3ff'>##elo </span> <span style='background-color:#f8f8ff'>##gen </span> <span style='background-color:#ffdede'>##ous </span> <span style='background-color:#f8f8ff'>leukemia </span> <span style='background-color:#e6e6ff'>( </span> <span style='background-color:#fff8f8'>am </span> <span style='background-color:#ffdede'>##l </span> <span style='background-color:#fefeff'>) </span> <span style='background-color:#fefeff'>; </span> <span style='background-color:#fefeff'>summary </span> <span style='background-color:#f8f8ff'>: </span> <span style='background-color:#fcfcff'>this </span> <span style='background-color:#fcfcff'>multi </span> <span style='background-color:#f2f2ff'>- </span> <span style='background-color:#fcfcff'>center </span> <span style='background-color:#fffafa'>, </span> <span style='background-color:#fcfcff'>open </span> <span style='background-color:#f3f3ff'>- </span> <span style='background-color:#fafaff'>label </span> <span style='background-color:#f3f3ff'>, </span> <span style='background-color:#fffcfc'>phase </span> <span style='background-color:#fefeff'>1b </span> <span style='background-color:#f2f2ff'>study </span> <span style='background-color:#fefeff'>will </span> <span style='background-color:#fff8f8'>evaluate </span> <span style='background-color:#fffefe'>the </span> <span style='background-color:#f6f6ff'>safety </span> <span style='background-color:#f0f0ff'>, </span> <span style='background-color:#fff6f6'>ph </span> <span style='background-color:#f6f6ff'>##arm </span> <span style='background-color:#fffcfc'>##aco </span> <span style='background-color:#fcfcff'>##kin </span> <span style='background-color:#fffefe'>##etic </span> <span style='background-color:#fcfcff'>##s </span> <span style='background-color:#fcfcff'>and </span> <span style='background-color:#fff8f8'>efficacy </span> <span style='background-color:#fffcfc'>of </span> <span style='background-color:#fff6f6'>ro </span> <span style='background-color:#f8f8ff'>##50 </span> <span style='background-color:#fff8f8'>##45 </span> <span style='background-color:#fcfcff'>##33 </span> <span style='background-color:#fffefe'>##7 </span> <span style='background-color:#fefeff'>in </span> <span style='background-color:#fefeff'>combination </span> <span style='background-color:#fffefe'>with </span> <span style='background-color:#f8f8ff'>cy </span> <span style='background-color:#fff8f8'>##tara </span> <span style='background-color:#fefeff'>##bine </span> <span style='background-color:#f3f3ff'>in </span> <span style='background-color:#fefeff'>patients </span> <span style='background-color:#fffefe'>with </span> <span style='background-color:#fafaff'>acute </span> <span style='background-color:#f3f3ff'>my </span> <span style='background-color:#fffcfc'>##elo </span> <span style='background-color:#fafaff'>##gen </span> <span style='background-color:#f6f6ff'>##ous </span> <span style='background-color:#f2f2ff'>leukemia </span> <span style='background-color:#fffefe'>. </span> <span style='background-color:#fefeff'>in </span> <span style='background-color:#fafaff'>arm </span> <span style='background-color:#f3f3ff'>a </span> <span style='background-color:#fcfcff'>, </span> <span style='background-color:#f8f8ff'>co </span> <span style='background-color:#fcfcff'>##hort </span> <span style='background-color:#fcfcff'>##s </span> <span style='background-color:#fffafa'>of </span> <span style='background-color:#fffcfc'>previously </span> <span style='background-color:#f8f8ff'>un </span> <span style='background-color:#fffefe'>##tre </span> <span style='background-color:#f8f8ff'>##ated </span> <span style='background-color:#f8f8ff'>patients </span> <span style='background-color:#f8f8ff'>deemed </span> <span style='background-color:#f8f8ff'>unsuitable </span> <span style='background-color:#f6f6ff'>for </span> <span style='background-color:#fcfcff'>standard </span> <span style='background-color:#fefeff'>induction </span> <span style='background-color:#fff6f6'>therapy </span> <span style='background-color:#f0f0ff'>will </span> <span style='background-color:#fcfcff'>receive </span> <span style='background-color:#fcfcff'>es </span> <span style='background-color:#fefeff'>##cala </span> <span style='background-color:#fefeff'>##ting </span> <span style='background-color:#fffefe'>oral </span> <span style='background-color:#fefeff'>doses </span> <span style='background-color:#f6f6ff'>of </span> <span style='background-color:#fffcfc'>ro </span> <span style='background-color:#fafaff'>##50 </span> <span style='background-color:#fafaff'>##45 </span> <span style='background-color:#f6f6ff'>##37 </span> <span style='background-color:#fefeff'>##7 </span> <span style='background-color:#fff8f8'>and </span> <span style='background-color:#fffefe'>cy </span> <span style='background-color:#ffeeee'>##tara </span> <span style='background-color:#fefeff'>##bine </span> <span style='background-color:#f8f8ff'>20 </span> <span style='background-color:#fffcfc'>mg </span> <span style='background-color:#fffcfc'>/ </span> <span style='background-color:#fffcfc'>m2 </span> <span style='background-color:#fafaff'>sub </span> <span style='background-color:#fffefe'>##cut </span> <span style='background-color:#fcfcff'>##aneous </span> <span style='background-color:#fcfcff'>##ly </span> <span style='background-color:#fefeff'>daily </span> <span style='background-color:#fcfcff'>for </span> <span style='background-color:#fcfcff'>days </span> <span style='background-color:#fcfcff'>1 </span> <span style='background-color:#fffefe'>to </span> <span style='background-color:#fefeff'>10 </span> <span style='background-color:#fff4f4'>of </span> <span style='background-color:#fffefe'>each </span> <span style='background-color:#fffcfc'>28 </span> <span style='background-color:#fff4f4'>- </span> <span style='background-color:#fff8f8'>day </span> <span style='background-color:#fcfcff'>cycle </span> <span style='background-color:#fff4f4'>. </span> <span style='background-color:#fffefe'>in </span> <span style='background-color:#fafaff'>arm </span> <span style='background-color:#fffefe'>b </span> <span style='background-color:#fff0f0'>, </span> <span style='background-color:#fcfcff'>co </span> <span style='background-color:#fafaff'>##hort </span> <span style='background-color:#fcfcff'>##s </span> <span style='background-color:#fefeff'>of </span> <span style='background-color:#fffcfc'>patients </span> <span style='background-color:#fffefe'>who </span> <span style='background-color:#fffefe'>have </span> <span style='background-color:#fcfcff'>re </span> <span style='background-color:#fffefe'>##la </span> <span style='background-color:#fcfcff'>##pse </span> <span style='background-color:#fffefe'>##d </span> <span style='background-color:#fffafa'>or </span> <span style='background-color:#fcfcff'>are </span> <span style='background-color:#fff8f8'>ref </span> <span style='background-color:#fcfcff'>##rac </span> <span style='background-color:#fffcfc'>##tory </span> <span style='background-color:#fffefe'>after </span> <span style='background-color:#fefeff'>at </span> <span style='background-color:#fffefe'>least </span> <span style='background-color:#fffcfc'>one </span> <span style='background-color:#fcfcff'>cy </span> <span style='background-color:#fffefe'>##tara </span> <span style='background-color:#fcfcff'>##bine </span> <span style='background-color:#f6f6ff'>/ </span> <span style='background-color:#fffcfc'>ant </span> <span style='background-color:#fefeff'>##hra </span> <span style='background-color:#fffafa'>##cy </span> <span style='background-color:#fcfcff'>##cl </span> <span style='background-color:#fffcfc'>##ine </span> <span style='background-color:#fffcfc'>containing </span> <span style='background-color:#fffafa'>regime </span> <span style='background-color:#fff6f6'>##n </span> <span style='background-color:#f8f8ff'>will </span> <span style='background-color:#fff6f6'>receive </span> <span style='background-color:#fcfcff'>es </span> <span style='background-color:#fffcfc'>##cala </span> <span style='background-color:#fffcfc'>##ting </span> <span style='background-color:#fefeff'>oral </span> <span style='background-color:#fffcfc'>doses </span> <span style='background-color:#fcfcff'>of </span> <span style='background-color:#fffafa'>ro </span> <span style='background-color:#fefeff'>##50 </span> <span style='background-color:#f8f8ff'>##45 </span> <span style='background-color:#fffafa'>##37 </span> <span style='background-color:#fff8f8'>##7 </span> <span style='background-color:#f8f8ff'>on </span> <span style='background-color:#fcfcff'>days </span> <span style='background-color:#fffafa'>1 </span> <span style='background-color:#f8f8ff'>to </span> <span style='background-color:#fff8f8'>5 </span> <span style='background-color:#f6f6ff'>and </span> <span style='background-color:#fff6f6'>cy </span> <span style='background-color:#ffeaea'>##tara </span> <span style='background-color:#fafaff'>##bine </span> <span style='background-color:#fffefe'>1 </span> <span style='background-color:#fff8f8'>gm </span> <span style='background-color:#fff8f8'>/ </span> <span style='background-color:#fffcfc'>m2 </span> <span style='background-color:#fffafa'>intra </span> <span style='background-color:#fefeff'>##ven </span> <span style='background-color:#fffcfc'>##ously </span> <span style='background-color:#fffefe'>on </span> <span style='background-color:#f8f8ff'>days </span> <span style='background-color:#fffafa'>1 </span> <span style='background-color:#fff6f6'>to </span> <span style='background-color:#fff6f6'>6 </span> <span style='background-color:#fffafa'>of </span> <span style='background-color:#fffcfc'>each </span> <span style='background-color:#fffafa'>28 </span> <span style='background-color:#fff0f0'>- </span> <span style='background-color:#fff4f4'>day </span> <span style='background-color:#fff2f2'>cycle </span> <span style='background-color:#fff8f8'>. </span> <span style='background-color:#fefeff'>patients </span> <span style='background-color:#fafaff'>will </span> <span style='background-color:#fcfcff'>receive </span> <span style='background-color:#fff8f8'>up </span> <span style='background-color:#fffafa'>to </span> <span style='background-color:#fafaff'>4 </span> <span style='background-color:#fffcfc'>cycles </span> <span style='background-color:#f8f8ff'>of </span> <span style='background-color:#fcfcff'>therapy </span> <span style='background-color:#fcfcff'>, </span> <span style='background-color:#fff4f4'>patients </span> <span style='background-color:#f6f6ff'>in </span> <span style='background-color:#f8f8ff'>arm </span> <span style='background-color:#fff6f6'>a </span> <span style='background-color:#fcfcff'>who </span> <span style='background-color:#fff2f2'>achieve </span> <span style='background-color:#f3f3ff'>hem </span> <span style='background-color:#fff4f4'>##ato </span> <span style='background-color:#f8f8ff'>##logic </span> <span style='background-color:#ffecec'>response </span> <span style='background-color:#fafaff'>may </span> <span style='background-color:#fffefe'>continue </span> <span style='background-color:#fff8f8'>additional </span> <span style='background-color:#fffcfc'>cycles </span> <span style='background-color:#fffafa'>until </span> <span style='background-color:#fff2f2'>disease </span> <span style='background-color:#fefeff'>progression </span> <span style='background-color:#fff6f6'>. </span> <span style='background-color:#fffefe'>; </span> <span style='background-color:#fff6f6'>phase </span> <span style='background-color:#fffefe'>: </span> <span style='background-color:#fff0f0'>phase </span> <span style='background-color:#fff0f0'>1 </span> <span style='background-color:#0000ff'>[SEP] </span>"},"metadata":{}},{"name":"stdout","text":"\n\n","output_type":"stream"}],"execution_count":44},{"cell_type":"markdown","source":"## Feature importance via attention\n\nTransformers have attention layers, which determine how much each token “attends” to other tokens. We can extract attention weights from the trained model:","metadata":{}},{"cell_type":"code","source":"import matplotlib.pyplot as plt\nimport seaborn as sns\n\n# -----------------------------\n# 1️⃣ Setup\n# -----------------------------\ndevice = torch.device(\"cuda\" if torch.cuda.is_available() else \"cpu\")\n\nmodel.to(device)\nmodel.eval()\n\n# -----------------------------\n# 2️⃣ Tokenize input\n# -----------------------------\ninputs = tokz(example_inputs[0], return_tensors=\"pt\")\ninputs = {k: v.to(device) for k, v in inputs.items()}\n\n# -----------------------------\n# 3️⃣ Forward pass to get attentions\n# -----------------------------\nwith torch.no_grad():\n    outputs = model(**inputs)\n\nattentions = outputs.attentions  # list of layers\nnum_layers = len(attentions)\nnum_heads = attentions[0].shape[1]\nseq_len = attentions[0].shape[2]\n\n# -----------------------------\n# 4️⃣ Aggregate attention across heads and layers\n# -----------------------------\n# Sum across heads, then average across layers\nattn_matrix = torch.stack(attentions).mean(0)       # [batch, heads, seq_len, seq_len]\nattn_matrix = attn_matrix[0].mean(0)               # average heads -> [seq_len, seq_len]\n\n# -----------------------------\n# 5️⃣ Compute per-token attention scores\n# -----------------------------\n# Sum attention each token receives from all others\ntoken_importance = attn_matrix.sum(dim=0).cpu().numpy()\ntokens = tokz.convert_ids_to_tokens(inputs[\"input_ids\"][0].cpu())\n\n# -----------------------------\n# 6️⃣ Select top N tokens for clarity\n# -----------------------------\ntop_n = 8\ntop_indices = np.argsort(token_importance)[-top_n:][::-1]  # descending\ntop_tokens = [tokens[i] for i in top_indices]\ntop_scores = token_importance[top_indices]\n\n# -----------------------------\n# 7️⃣ Plot clean bar chart\n# -----------------------------\nplt.figure(figsize=(8,4))\nplt.bar(top_tokens, top_scores, color='skyblue')\nplt.title(\"Top Tokens by Aggregated Attention\")\nplt.ylabel(\"Attention Score\")\nplt.xticks(rotation=45)\nplt.show()\n","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-13T14:24:34.067039Z","iopub.execute_input":"2025-11-13T14:24:34.067669Z","iopub.status.idle":"2025-11-13T14:24:34.391916Z","shell.execute_reply.started":"2025-11-13T14:24:34.067644Z","shell.execute_reply":"2025-11-13T14:24:34.390974Z"}},"outputs":[{"traceback":["\u001b[0;31m---------------------------------------------------------------------------\u001b[0m","\u001b[0;31mTypeError\u001b[0m                                 Traceback (most recent call last)","\u001b[0;32m/tmp/ipykernel_950/3418896329.py\u001b[0m in \u001b[0;36m<cell line: 0>\u001b[0;34m()\u001b[0m\n\u001b[1;32m     23\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     24\u001b[0m \u001b[0mattentions\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0moutputs\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mattentions\u001b[0m  \u001b[0;31m# list of layers\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 25\u001b[0;31m \u001b[0mnum_layers\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mlen\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mattentions\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m     26\u001b[0m \u001b[0mnum_heads\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mattentions\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;36m0\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mshape\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;36m1\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     27\u001b[0m \u001b[0mseq_len\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mattentions\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;36m0\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mshape\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;36m2\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n","\u001b[0;31mTypeError\u001b[0m: object of type 'NoneType' has no len()"],"ename":"TypeError","evalue":"object of type 'NoneType' has no len()","output_type":"error"}],"execution_count":45}]}